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1 Abstract  1 
1. Abstract 
The developmental program of Epithelial Mesenchymal Transition (EMT) is assumed to be 
involved in tumor progression, enabling cancer cells to spread from the primary tumor and 
form metastasis in distant tissues. At least in some cases, disseminated tumor cells display 
tumor-initiating properties similar to stem cells. In addition, these cells tend to resist chemo-
therapy. However, it is unclear how cells gain the competency to escape chemotherapeutic 
treatment upon EMT.  
In order to investigate the role of EMT in chemotherapeutic resistance and the underlying 
mechanisms, we used a HMLE RAS (Human Mammary Large T-Antigen immortalized Epi-
thelial HaRas expressing cell) model system. This EMT system is composed of two different 
cell lines. On the one hand, the so called 24
+
 RAS cells display an epithelial morphology and 
lack efficient migration. On the other hand, the MSP RAS cells (mesenchymal subpopulation) 
that originate from the 24
+
 RAS cells have undergone EMT, accompanied by a mesenchymal 
cell shape and high invasivity. In this study, we applied several chemotherapeutic treatments 
to both cell lines to assess their response to chemotherapy.  
We found that, in contrast to 24
+
 RAS cells, MSP RAS cells are resistant to the chemothera-
peutics Cisplatin, Doxorubicin and Neocarzinostain, but also to the death ligands Trail and 
TNFα, as seen by reduced PARP and Caspase 3 cleavage upon treatment. Beyond that, we 
showed that the anti-apoptotic Bcl-2 family member Bcl-xL is overexpressed in MSP RAS 
cells, in comparison to 24
+
 RAS, which enables former cells to survive chemotherapy and to 
continue proliferation after treatment.  
We have demonstrated that retrovirus-mediated Bcl-xL overexpression in 24
+
HMLE renders 
these cells chemoresistant, as well. Conversely, knocking down Bcl-xL in MSP RAS cells 
rendered them sensitive to death stimuli. Strikingly, we found Bcl-xL overexpressed in human 
breast cancer cells at the tumor-stroma-interface, suggesting a general role of Bcl-xL in mi-
grating cancer cells. We found that inhibition of Bcl-xL with the BH3 mimic Gossypol results 
in chemosensitivity of MSP RAS cells. The same observation was obtained upon Bcl-xL de-
stabilization, mediated by the inhibition of the chaperone HSP90 in vitro and in vivo, demon-
strating that we found an option to overcome chemoresistance of cells that have undergone 
EMT.  
In conclusion, our data reveal Bcl-xL as a key mediator of apoptosis-resistance in cells upon 
EMT. We propose a causal relation between EMT, Bcl-xL overexpression and chemo-
resistance, and we suggest Bcl-xL as a promising target in cancer therapies. 
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2. Introduction 
2.1 Need for new cancer therapies to eliminate subpopulations of tumor cells 
Cancer represents a major health problem worldwide. Ferlay et al. estimated 3.45 million new 
cases of cancer in Europe in 2012, with the most frequent cancer type being female breast 
cancers with about 464.000 cases [1]. The main difficulty in eliminating cancer is the occur-
rence of metastases that differ from their origin, exhibit increased invasiveness and are inac-
cessible for conventional chemotherapy causing cancer regrowth. On the contrary, new re-
search has found that chemo- and radiotherapy of primary tumors can encourage the devel-
opment of metastases [2]. Correspondingly, metastases are associated with a poor prognosis 
for cancer patients [3]. Hitherto, it was assumed that metastatic cells do not differ from the 
primary tumor and were therefore not considered for cancer therapy. However, it was recently 
published that the gene expression patterns of tumor cells that survived chemotherapy differs 
from cells belonging to the primary tumor, and this particularly involved genes govern cell 
cycle progression and cell survival. Consistent with these findings, it could be observed that f. 
e. breast cancers exhibit a subpopulation of cells that contain tumor initiating properties asso-
ciated with resistance to chemotherapies as compared to the major cell population of the dif-
ferentiated tumor [4]. Furthermore, conventional therapies targeting the primary tumor indeed 
result in tumor regression but do not protect from tumor cells causing a relapse associated 
with a lack of chemosensitivity. The outcome of chemotherapy to metastasis was not consid-
ered so far, but understanding this issue will enable clinics to develop new cancer therapies 
and demand progressive research in the field of chemotherapeutic resistance [5].  
2.2 Chemotherapy 
Nowadays, one of the most prominent medical challenges is cancer therapy. While surgery 
and irradiation are specifically applied to solid tumors, their combination with chemotherapy 
is essential to eliminate disseminated tumors and metastasis. Since cancer cells are predomi-
nantly fast replicating cells, chemotherapeutics often target the cell cycle and inhibit cell 
growth and reproduce [6]. Chemotherapy can directly affect cell division by disabling the mi-
totic spindle, like the taxanes or inhibit growth signalling pathways. However, the most nota-
bly used chemotherapeutics are agents that cause DNA damage and therefore prevent cell cy-
cle progression and induce cell death [7]. Lesions that occur during the S-phase of the cell cy-
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cle can additionally disable replication fork progression followed by the generation of DNA 
double-strand breaks that mainly result in the induction of programmed cell death in cancer 
cells [7].  
Anti-tumor agents can be classified into several groups according to their mechanism of ac-
tion [8]. The first group contains nucleoside analogues including the antimetabolites Gem-
citabine and 5-Fluorouracil (5-FU). These compounds interfere specifically with the S-phase 
of the cell cycle and provoke the termination of DNA replication. The second group compris-
es enzyme inhibitors. These anti-tumor agents specifically act on enzymes, which are in-
volved in DNA replication. On the one side, there are DNA methyltransferase inhibitors such 
as 2´-deoxy-5-azacytidine that result in missing DNA methylation and therefore evoke the ac-
tivation of silenced genes, including tumor-suppressor genes. On the other side, anthracy-
clines like Doxorubicin and Daunorubicin induce double-strand breaks by the inhibition of 
topoisomerase II, an enzyme that relaxes supercoiled DNA by cleavage and religation [9; 10]. 
Additionally, anthracyclines are able to intercalate in the DNA and thereby stabilize the DNA 
duplex and prevents the helicase from separating the strands [11]. The last group of chemo-
therapeutics directly damages the DNA resulting in the induction of DNA adducts, DNA 
strand breaks and DNA-protein cross links which immediately trigger the DNA damage re-
sponse [7]. Alkylating agents, like Cyclophosphamide, attach alkyl groups to the DNA and 
thereby inhibit DNA replication, while platinum agents induce DNA crosslinks and DNA ad-
ducts which causes the inhibition of DNA replication and transcription. Finally the radiomi-
metic DNA cleaving agents like Neocarzinostatin (NCS) evoke single- and double-strand 
breaks.  
Unfortunately, chemotherapeutics impact healthy cells as well, especially tissues with high 
turnover rates such as the bone marrow or the epithelium of the gastrointestinal tract. The ap-
plication of chemotherapeutic combinations attempts to minimize harmful secondary effects 
of chemotherapy while coincidentally increasing its anti-tumor-activity [6]. 
2.2.1 Particularized view on chemotherapy used in this thesis 
2.2.1.1 Platinating agents 
This group of chemotherapeutics includes the platinum based chemotherapeutic drugs Cispla-
tin, Carboplatin and Oxaliplatin. These agents are used for a wide range of solid tumors and 
represent an effective therapy for head, neck, testicular, ovarian, bladder, prostate and lung 
cancer inducing DNA lesions and therefore inhibiting DNA replication [12].  
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The anti-tumor activity of Cisplatin was first described by Rosenberg et al. in 1969 [13]. Cis-
platin is a cytostatic agent which contains a complex bonded platinum atom. Due to the low 
chloride concentrations present in the cytoplasm, the platinum complex becomes activated by 
the replacement of chloro-ligands in to water molecules. Thereby, the molecule obtaines a 
positive charge and initiates the formation of mono-adducts between the platinum atom and 
DNA, particularly at the nucleophilic N-atoms of the purines, which induce bivalent intra- 
and interstrand cross links [14; 15]. DNA replication stops and strand breaks are evoked re-
sulting in a G2-phase arrest of the cell cycle and the initiation of DNA damage repair or pro-
grammed cell death (Figure 2.1) [16].  
 
 
Figure 2.1: Overview of the cytotoxic pathway of Cisplatin.  
Cisplatin translocates into the cell and is activated by replacing the chloro-ligands into water molecules followed 
by binding to DNA. Therefore Cisplatin induces intra- and interstrand crosslinks. The DNA lesions are either re-
paired or programmed cell death is induced. Referring to Alderden et al. [17]. 
 
To overcome the resistance that Cisplatin treated tumors could develop, either during therapy 
cycles, as was observed for ovarian cancer, or by the acquisition of intrinsic resistance, as ob-
served for prostate, colorectal, lung or breast cancer patients, thousands of Cisplatin ana-
logues were synthesized. These “second- and third-generation” platin drugs, such as Car-
boplatin, which lacks nephrotoxicity, is less toxic to the gastrointestinal tract and less neuro-
toxic compared to Cisplatin have receive worldwide approval and clinical use [18; 19]. In 
contrast to Cisplatin, Carboplatin contains cyclobutane-1,1-dicarboxylate-ligands which me-
diates good aqueous solubility and greater stability because of the six-membered ring with a 
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platinum ion. These properties illustrate that Carboplatin displays a spectrum of activities 
comparable to Cisplatin but is better tolerated and therefore predominantly clinically used 
[19]. Interestingly, phase II trials for metastatic breast cancers have shown that Carboplatin 
alone produced objective response rates of 20-35% [20; 21]. Additionally, synergistic anti-
tumor efficacies were observed in phase II and III trials for a combination therapy with 
Paclitaxel or Trastuzumab, favoring Carboplatin as a standard active substance for cancer-
therapies for metastatic breast cancer, especially for patients that fail to respond to anthracy-
cline-based therapy [22; 23; 24; 25].  
2.2.1.2 Anthracyclines 
Anthracyclines were first described in the 1960´s by Brockmann et al. and are derived from 
Streptomyces peucetius. They possess anti-tumor activity against breast cancer, sarcoma and 
lymphoma [9; 26]. Anthracyclines are red aromatic polyketides exhibiting a heterogeneous 
structure due to distinctive aglyconic and sugar residues. The most prominent agents in this 
group are Doxorubicin and Daunorubicin, followed by their derivatives Epirubicin and Ida-
rubicin, respectively. As reviewed by Gewirtz, anthracyclines display a wide range of cellular 
interventions. First anthracyclines induce adduct formation and cross linking of the DNA as 
well as the induction of DNA damage through interference with topoisomerase II. Further-
more, anthracyclines form a ternary complex with DNA and topoisomerase II which induces 
DNA single- and double-strand breaks, followed by G1- or G2-arrest. Moreover, the incur-
rence of reactive oxygen species as superoxide anion (O
2-
) and hydrogen peroxide (H2O2) dur-
ing the biotransformation of anthracyclines results in oxidative damage of the DNA as well as 
the cell membranes [9]. Additional studies have shown that anthracyclines interfere with mac-
romolecular biosynthesis and therefore inhibit DNA synthesis in the tumor cell. Anthracy-
clines are able to intercalate in DNA and also disable the DNA polymerase [27]. In the end, a 
clear consequence of treatment with anthracyclines is damaged DNA triggering the DNA 
damage response and subsequent induction of programmed cell death [9; 27].  
2.2.1.3 Neocarzinostatin 
Neocarzinostatin (NCS) is an antibiotic from Streptomyces carzinostaticus that has anti-tumor 
activity. The acidic polypeptide is cross-linked with two disulfide bridges and consists of 109 
amino acid residues. Hence NCS belongs to the family of macromolecular antibiotics with the 
ability to inhibit DNA synthesis and induce DNA damage [28; 29]. The biological activity of 
NCS is mediated by a non-covalently bound chromophore which binds to DNA in a two-step 
process. It first binds externally to a specific DNA sequence, followed by the intercalation of 
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the chromophore between adjacent DNA base pairs. The latter induces single- and double-
strand breaks particularly in A-T rich regions [30; 31]. In the 1980´s, clinical trials were per-
formed in Japan testing NCS for chemotherapeutical use. Unfortunately various types of toxic 
manifestations have been demonstrated whereby NCS could not gain acceptance for clinical 
use [32; 33]. However, as a radiomimetic DNA cleaving agent, NCS is a valuable agent for 
laboratory use.  
2.2.2 Chemoresistance and mechanisms involved 
The efficacy of chemotherapy is limited by the acquisition of chemoresistance in cancer cells. 
Thereby tumors are either intrinsically resistant to chemotherapy prior to treatment, or tumors 
that were originally chemosensitive gain resistance during cancer therapy. Most notably, 
chemoresistance does not only concern the anti-tumor agents that were initially used; rather 
tumors become cross-resistant to other chemotherapeutics with a different mode of action as 
well [34]. Another aspect of ineffectiveness of chemotherapeutic treatment involves the sur-
vival of a population of tumor cells during treatment that subsequently initiate the cancer re-
growth upon termination of treatment [35]. Drug-resistance includes various factors that af-
fect chemo-response and can occur at several levels (Figure 2.2). On the one hand, there are 
mechanisms that limit the doses of chemotherapy reaching the tumor or affect the tumor mi-
croenvironment. On the other hand, cancer cell specific mechanisms that are pointed out in 
the following sections include drug transport into the cells, drug inactivation, alteration of the 
drug target and processing drug-induced damage and finally the prevention of apoptosis [34].  
 
 
Figure 2.2: Schematic illustration of the mechanisms involved in chemoresistance in cancer cells.  
Legend on the next page. 
2 Introduction  7 
Figure 2.2: Schematic illustration of the mechanisms involved in chemoresistance in cancer cells. Efflux 
and import occur by means of membrane-associated transporters including ABC-transporter and multi-drug re-
sistance protein (MRP) family members. Referring to Gottesman [36]. 
2.2.2.1 Drug influx and efflux 
Altered drug influx and efflux is often involved in enhanced chemoresistance. In particular, it 
is well known that changes in the expression of ABC-transporters, especially the P-
glycoprotein and the multi-drug resistance protein (MRP) family, are involved in increased 
efflux of chemotherapeutic drugs [34]. Hydrophobic anti-tumor agents, including taxanes and 
anthracyclines, are actively transported out of the cell by these proteins [34]. For Cisplatin, it 
is known that the Cu-transporter ATP7A and 7B are connected to its export. Thereby, ectopic 
expression of ATP7B results in diminished Cisplatin sensitivity because of a decrease in Cis-
platin accumulation. Interestingly, the ectopic expression of ATP7A evokes the accumulation 
of Cisplatin in endosomes inhibiting its effect on DNA [37]. However, Cisplatin has not been 
described as a substrate for the P-glycoprotein and therefore not carried out by these efflux 
pumps [15].  
2.2.2.2 Drug inactivation 
Furthermore drug inactivation has been shown to play an important role in chemoresistance, 
which reduces the amount of anti-tumor agent that is available to reach their targets in cancer 
cells [34]. It has been shown that the activated platinating agents, including Cisplatin, Car-
boplatin and Oxaliplatin are able to react with thiol-containing molecules, like glutathione 
(GSH) and metallothioneins in the cytoplasm. Glutathione is an anti-oxidant in the body that 
prevents oxidative stress. Binding of Cisplatin to Glutathione results in adduct formation as-
sociated with detoxification of Cisplatin which either traps Cisplatin in the cell or results in an 
increased efflux of Cisplatin by unidentified organic anion pumps [38; 39]. Another aspect of 
missing drug activation, reflects the fact that several chemotherapeutics have to be metabo-
lized into an active form in the body. The topoisomerase I inhibitor Camptothecin, for exam-
ple, is metabolized by a carboxylesterase, which is found to be less active in cancer cells [40].  
2.2.2.3 Drug targets and regulatory proteins 
Generally, the mutation of chemotherapeutic targets or alteration of their expression levels 
has a substantial impact on drug resistance. Lang et al. have shown that altered topoisomerase 
II expression or activity results in drug resistance against topoisomerase II inhibitors and 
cross-resistance to anthracyclines like Doxorubicin [41]. Additionally, the thymidylate syn-
thase (TS), which is an essential enzyme for the biosynthesis of dTMP from Uracil and indis-
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pensable for DNA repair and replication, is an important target for chemotherapy. TS is inhib-
ited by 5-FU; correspondingly high levels of TS are associated with resistance to 5-FU [42]. 
Importantly, besides alterations in the expression of drug targets, alterations in the expression 
of oncogenes like c-fos and c-jun and tumor suppressors, such as p53, are also involved in cel-
lular resistance. The increased expression of c-fos and c-jun for example is found to be asso-
ciated with Cisplatin-resistant cells while the down-regulation of these genes reverses re-
sistance to Cisplatin. Importantly, Cisplatin treatment induces c-fos and c-jun expression, 
which results in increased expression of genes that contain binding sites for the transcription 
factor AP-1 (activator protein 1). AP-1 is a transcription factor complex, which consists of 
Fos and Jun heterodimers. AP-1 regulated genes includes c-myc and metallothioneins that are 
involved in cell proliferation and in the end cause chemoresistance [15].  
2.2.2.4 DNA damage repair 
DNA damage caused by chemotherapy is either induced directly, e.g. by platinum agents, or 
indirectly, as it is known for 5-FU and topoisomerase inhibitors. Induction of DNA damage is 
followed by DNA repair and in the case of extensive damage by programmed cell death. The 
efficiency of cancer cells to repair DNA can determine their resistance to chemotherapy [34]. 
For example, adducts that were formed by Cisplatin and DNA are repaired by nucleotide ex-
cision repair (NER) and homologous recombination. Cells that are deficient in NER are more 
sensitive to Cisplatin than the wildtype cells. However, restoration of NER activity is accom-
panied by a decrease in drug sensitivity. Moreover, it has been published that Cisplatin treat-
ment leads to increased levels of the excision repair cross-complementing 1 protein (ERCC1) 
which is a rate-limiting factor of the NER system and is associated with Cisplatin resistance 
[15; 34]. On the other hand, several studies demonstrated that Cisplatin resistance is accom-
panied by adduct tolerance and an increase in the ability to replicate past Cisplatin adducts 
[43; 44].  
2.2.2.5 Inhibited apoptosis 
Treatment of tumor cells with chemotherapy involves a lot of different signalling pathways 
acting together. As mentioned above a major chemotherapeutic activity is the induction of 
DNA damage followed by apoptosis. Since tumor cells exhibit modifications in the induction 
of apoptosis following chemotherapy, this is an important issue with regard to chemothera-
peutic resistance. Failure to induce apoptosis can be reasoned by overexpression of anti-
apoptotic proteins like Bcl-2 or the decreased expression of pro-apoptotic proteins, such as the 
death receptor Fas [45]. Apoptosis can be regulated by an intrinsic signaling pathway mediat-
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ed via the mitochondria, or extrinsically via activation of the death receptors. In cancer cells 
both apoptosis inducing pathways can be disrupted leading to a failure to undergo apoptosis 
after chemotherapeutic treatment. Many solid tumor cells exhibit increased expression of the 
protein Bcl-2, preventing activation of the caspase cascade downstream of the mitochondria. 
On the other hand, down-regulation of the anti-apoptotic proteins including Bcl-xL is associ-
ated with chemosensitivity [46; 47]. It was also observed that Cisplatin-resistant cells display 
reduced activation of the JNK signalling pathway. This pathway activates apoptosis by modu-
lating the activities of mitochondrial pro- and anti-apoptotic proteins through their phosphory-
lation state [48]. Cisplatin-resistant ovarian carcinoma and lymphoma cells were especially 
found to exhibit no JNK activation [15; 49]. Additionally, in contrast to apoptosis inhibition, 
cancer cells show continuous activation of pro-survival pathways as well. For example, the 
protein tyrosine kinases (PTKs) regulate the anti-apoptotic signaling pathways that have been 
described to be highly over expressed in tumor cells. A well-known family of the PTKs is the 
epidermal growth receptor (EGFR) family which includes EGFR and Her2. The binding of 
growth factors such as EGF or TGFα to these receptors leads to the activity of pro-survival 
and proliferative pathways [47]. The activation of the PI3-kinase/Akt and STAT pathways are 
especially known to be highly induced in tumors such as breast, head and neck cancer, respec-
tively [50]. Moreover, the overexpression of EGFR and Her2 is accompanied by chemo-
resistance and a poor prognosis for cancer patients. 15-25% of breast cancers contain high ex-
pression levels of Her2. To block Her2, the specific antibody Trastuzumab that targets mem-
brane bound Her2 is clinically used in combination with chemotherapy, resulting in increased 
response rates [47].  
2.3 Apoptosis 
Apoptosis is an important kind of programmed cell death; it is a genetically determined 
mechanism by which cells are eliminated, that normally occurs during development, mainte-
nance of homeostasis and to eliminate cells that can be threat to the organism, such as virus-
injected or tumor cells [51]. The term of apoptosis was firstly described by Kerr et al. in 1972 
[52] based on morphological cell changes and formation of “apoptotic bodies”. However, the 
phenomenon itself was observed 100 years before by Carl Vogt in 1842 [53]. Apoptosis is 
characterised by a series of morphological and biochemical changes that are strictly deter-
mined. Apoptotic cells typically lose contact with neighbouring cells, show deformation and 
lose cell volume. Apoptosis is accompanied by nuclear condensation, chromatin aggregation 
and finally endonucleolytic DNA fragmentation into multiples of 185 base pairs. Subsequent-
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ly, the membrane potential of the mitochondria collapses and pH-values decrease. Upon DNA 
fragmentation the cell decomposes by mouldering into apoptotic bodies which contain cyto-
sol, the condensed chromatin and organelles. The apoptotic bodies are phagocytised by mac-
rophages and thus removed from the tissue, preventing the release of inflammatory cytokines 
[54; 55]. The point of no return during apoptosis is characteristically marked by the proteolyt-
ic cleavage of PARP and is correspondingly a hallmark of apoptosis. PARP is usually activat-
ed by DNA strand breaks to stabilize those and the chromatin. However, if the DNA lesions 
are not repairable the cell induces irreversible apoptosis [56; 57].  
Apoptosis induction can be divided into two main pathways: On the one hand, the intrinsic 
mitochondria-mediated induction of apoptosis that is triggered by cellular stress, chemothera-
py and irradiation and is dependent on intracellular checkpoint proteins [55]. On the other 
hand, the extrinsic death receptor-induced pathway mediated for example by Fas or Trail re-
ceptors. Apoptosis induction frequently leads to the activation of several signalling pathways 
that shift the balance from anti- to pro-apoptotic proteins associated with cell cycle arrest and 
activation of the caspase cascade (Figure 2.3) [54].  
 
 
Figure 2.3: Extrinsic and intrinsic apoptosis signalling pathways.  
Extrinsic apoptosis pathway: Death ligands bind to the death receptors which causes their oligomerisation. Sub-
sequently, the adaptor molecule FADD (fas-associating protein with death domain) is recruited to the intracellu-
lar death domain (DD) of the receptors forming the death inducing signaling complex (DISC) which results in 
the recruitment and processing of pro-caspase 8. Caspase 8 either directly induces programmed cell death or 
cleaves the BH3 only protein Bid. Truncated Bid (tBid) translocates to the mitochondria induces cytochrome c 
release and therefore activates Caspase 3 dependent cell death. tBid connects the two apoptosis pathways. Intrin-
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sic apoptosis pathway: Cellular stress leads to the interaction of the Bcl-2 family members Bax and Puma with 
the mitochondrial outer membrane causing permeabilization and release of cytochrome c. Cytochrome c acts as 
secondary messenger forming the apoptosome with Apaf-1 and pro-caspase 9. Caspase 9 is processed and sub-
sequently activates Caspase 3 and 6 initiating the caspase cascade. The mitochondria membrane permeabiliza-
tion is inhibited by anti-apoptotic members of the Bcl-2 family. Moreover the pro-apoptotic factor Smac/Diabolo 
that is released from the mitochondria at later stages of the programmed cell death inhibits the IAPs (inhibitors 
of apoptosis) supporting apoptosis induction. Adapted from K. Lauber, Dissertation at the University of Tübing-
en [58]. 
There are three different mechanisms characterized by which a cell gains resistance to apopto-
sis induction. On the one hand, the disruption of the balance between pro-and anti-apoptotic 
proteins which is regulated by several proteins including p53 but also oestrogens in the breast 
epithelium. At that, it is known that oestrogens are able to induce anti-apoptotic Bcl-2-family 
members in breast epithelial cells as well as in several breast cancer cell lines causing pro-
longed survival of these cells [59; 60; 61]. On the other hand, the reduction of caspase activity 
and finally the absence of death receptor signalling play an important role in the acquisition of 
apoptosis-resistance [61]. 
2.3.1 Caspases 
Caspases are central initiators and executioners of apoptosis [54]. Caspases are cysteine-
dependent aspartate-directed proteases that usually occur in the cell as inactive pro-enzymes. 
Once activated they can trigger other caspases and lead to the amplification of the apoptotic 
signalling pathway [62]. Caspases are synthesized as pro-caspases containing a pro-domain 
on their N-terminus, followed by a large and small subunit. During caspase activation the pro-
domains are cleaved off by other caspases and the small and large subunits are separated be-
hind the aspartate residues by a proteolytical process [53]. In the end, the active caspases are 
formed by heterotetramers consisting of two small and two large subunits [54; 62]. Overall 14 
mammalian caspases have been found and can be divided into three functional groups: the ini-
tiator caspases, including Caspase 2, 8, 9 and 10 characterized by long pro-domains; the ef-
fector caspases-, such as Caspase 3, 6 and 7 containing short pro-domains; and finally in-
flammatory caspases involved in cytokine activation named Caspase 1, 4, 5, 11, 12 and 13 
[53; 62].  
The most important effector caspase is Caspase 3, which is activated by any of the initiator 
caspases and is able to activate the endonuclease Caspase-Activated DNase (CAD). General-
ly, CAD is complexed with its inhibitor forming ICAD. However, in apoptotic cells activated 
Caspase 3 cleaves ICAD and releases CAD that subsequently degrades the chromosmal DNA 
[51]. Moreover, effector caspases cleave specific protein substrates, including the pro-
caspases themselves to amplify the death signal [54].  
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In mammals, several proteins act as inhibitors for caspases belonging to the inhibitor of apop-
tosis (IAP) family such as XIAP and survivin [62]. IAPs conduct their function through direct 
interaction with pro-caspase 9 associated with inhibition of its processing, competing for 
Apaf-1 binding instead of Caspase 9 and the direct inhibition of active caspases [61].  
The extrinsic and intrinsic pathways of apoptosis are associated and affect each other while 
coming together at the same point where Caspase 3 and Caspase 7 are activated followed by 
cell shrinkage, chromatin condensation and DNA fragmentation and finally degradation of 
nuclear and cytosolic proteins [62].  
2.3.2 Extrinsic apoptosis induction 
The induction of the extrinsic apoptotic signalling pathway is triggered by the binding of ex-
tracellular death ligands to the plasma membrane associated death receptors. The death recep-
tors belong to the tumor necrosis factor receptor (TNF-R) superfamily including DR4, DR5 
TNF-R1 and Fas [63]. The specific binding of the death ligands is mediated by a cysteine rich 
extracellular subdomain that trimerizes upon ligand binding and results in the activation of the 
respective receptor. The intracellular part of the death receptors contains a death domain (DD) 
that recruits adaptor molecules, such as FADD (Fas-associating death domain), upon ligand 
binding. The adaptor molecules themselves additionally contain a so called death effector 
domain (DED) which associates with pro-caspase 8, all together forming the death-inducing 
signalling complex (DISC) [62]. The formation of DISC results in the autocatalytic activation 
of Caspase 8 which then processes downstream effector caspases ending up in programmed 
cell death [54]. Cells that induce this direct and caspase-dependant pathway are also described 
as type I cells [64]. In contrast, there are also type II cells that are not able to induce a signal-
ling caspase cascade that is strong enough to result in cell death. Alternatively, these type II 
cells make use of activation of the mitochondria-mediated apoptotic signalling pathway. In 
this case Caspase 8 is also able to cleave the BH3 only protein Bid. The truncated form of 
Bid, tBid, translocates to the mitochondria where it induces the release of cytochrome c and 
evokes the activation of Caspase 9 and Caspase 3, ultimately resulting in cell death [53].  
2.3.3 Intrinsic apoptosis induction 
The pivotal mediator of the intrinsic apoptotic signalling pathway is the mitochondrion. The 
activation of intrinsic apoptosis takes place by cellular stress including DNA damage and oxi-
dative stress, but also cytostatic agents and irradiation. Consequently, levels of pro-apoptotic 
proteins, such as Bax increase, followed by the permeabilization of the mitochondrial mem-
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brane and release of pro-apoptotic factors, such as cytochrome c, that in the end triggers the 
caspase cascade [54; 65]. 
A major event during the induction of intrinsic apoptosis is the disruption of the mitochondri-
al inner transmembrane potential and the permeability transition. This means the abrupt per-
meabilization of the inner mitochondrial membrane which results in the release of pro-
apoptotic factors into the cytoplasm [54]. Therein, the pro- and anti-apoptotic members of the 
Bcl-2 family are involved. While the pro-apoptotic Bcl-2 family proteins promote the release 
of cytochrome c, anti-apoptotic members cause its inhibition [61]. Upon receiving the death 
signal, the pro-apoptotic Bcl-2 family members undergo a conformational change and subse-
quently target and integrate in the mitochondrial outer membrane [66]. Integration into the 
mitochondrial membrane contributes to formation of proteolipid pores which in turn results in 
the loss of membrane integrity and lead to the release of two main groups of pro-apoptotic 
factors from the intermembrane space into the cytoplasm. The first group contains cyto-
chrome c, Smac /Diabolo and the serine protease HtrA2/Omi. These proteins activate the 
caspase-dependant mitochondrial pathway [51]. In the cytoplasm, cytochrome c acts as a sec-
ondary messenger and supports the conformational change of Apaf-1. This results in the 
building of the apoptosome together with pro-caspase 9. This interaction enables the matura-
tion of pro-caspase 9 to Caspase 9 which is executed by a two-step cleavage event as de-
scribed above, followed by the activation of the effector caspases, Caspase 3 and Caspase 7. 
In contrast, Smac/Diabolo and HtrA2/Omi act as inhibitors for IAPs [53]. The second group 
of pro-apoptotic factors released from the mitochondria are AIF (apoptosis inducing factor), 
endonuclease G and CAD occurring after the cell has committed to die. AIF causes fragmen-
tation of the DNA and chromatin condensation. Together with endonuclease G, they acting 
independent of caspases [51]. The strict control on induction of the intrinsic apoptotic signal-
ling pathway is subjected to the interplay of pro- and anti-apoptotic members of the Bcl-2 
family which is pointed out in the next paragraph [67].  
2.3.4 Bcl-2 family 
Bcl-2 was initially found to be a proto-oncogene which plays an important role in follicular b-
cell lymphoma. But later on it was discovered that at least 19 Bcl-2 family members are pre-
sent in mammalian cells balancing the induction of apoptosis [67]. These members contain at 
least one of the four conserved Bcl-2 homology (BH) domains designated BH1, BH2, BH3 
and BH4 (Figure 2.4) [66]. According to their function and structure, the Bcl-2 family mem-
bers can be divided into three classes: First are the anti-apoptotic proteins including Bcl-2, 
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Bcl-xL, Mcl-1 and Bcl-W. These members contain all four BH domains and are initially inte-
gral membrane proteins. They are present in the membranes of the mitochondria, endoplas-
matic reticulum or the nucleus and maintain the integrity of the mitochondria. Second are the 
pro-apoptotic proteins Bak and Bax which are able to induce mitochondria outer membrane 
permeabilization [66]. These apoptotic proteins contain BH1, BH2 and BH3 but not BH4. In 
the third category are the “BH3 only” pro-apoptotic members, which include Bid, Bim, Bad, 
Bik, Bmf, Bnip3, Hrk, Noxa and Puma. These members share sequence homology only with-
in the BH3 domain and the fact that the amphipatic α-helical BH3 domain contains a critical 
death domain [66; 67].  
The anti-apoptotic members Bcl-2 and Bcl-xL are localized to the mitochondrial membrane, 
while the pro-apoptotic proteins either locate diffusely in the cytoplasm or associated with the 
mitochondrial membrane as well. During the induction of apoptosis BH3 only members get 
activated by transcriptional up regulation (Bax, Puma, Noxa), subcellular relocalization 
(Bim), dephosphorylation (Bad) or proteolysis (Bid). The activation of the BH3 only mem-
bers blocks the activity of the anti-apoptotic Bcl-2 proteins in inhibiting pro-apoptotic Bcl-2 
members. Additionally, it is assumed that they directly induce the conformational change of 
Bak and Bax which results in the exposure of the pro-apoptotic BH3 domain and their oli-
gomerization. Subsequently, they insert into the mitochondrial membrane, form pores and 
elicit cytochrome c release [54; 65; 67; 68]. 
 
 
Figure 2.4: Overview of the Bcl-2 family members.  
The Bcl-2 family consists of three subfamilies: the anti-apoptotic Bcl-2 proteins that promote cell survival, while 
the pro-apoptotic proteins and BH3 only pro-apoptotic proteins evoke apoptosis. Typically, Bcl-2 family mem-
bers contain up to four conserved Bcl-2 homology (BH) domains designated BH1, BH2, BH3 and BH4. BH3 
domain only members display sequence homology only within the BH3 domain which contains a critical death 
domain. TM: transmembrane domain. Referring to Zimmermann et al. [67] 
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2.3.4.1 Bcl-xL 
Bcl-xL is an anti-apoptotic protein belonging to the Bcl-2 family. The gene name of Bcl-xL is 
Bcl2L1. Due to the fact that an intron separates the coding region in Bcl2L1 at the same posi-
tion as Bcl-2, it is suggested that they evolved by duplication and are closely related [69]. Al-
ternative splicing of Bcl2L1 leads to the production of several isoforms. A long version of 
Bcl2L1, namely Bcl-xL contains all four BH domains and inhibits programmed cell death. 
However, an isoform missing 68 amino acids which cover the BH1 and BH2 domain is called 
Bcl-xS and antagonizes Bcl-xL. Bcl-xL and Bcl-xS are generated by alternative 5´splice site 
selection in exon 2 that is regulated by two ceramide-responsive RNA cis elements (CRCEs) 
[70]. Bcl-xS is highly expressed in cells with high turnover such as developing lymphocytes, 
whereas Bcl-xL mRNA is found in tissues containing long-lived postmitotic cells such as the 
adult brain. Bcl-xL expression is more widespread than Bcl-xS which is only present in some 
tissues including the thymus and lymph nodes [70]. Bcl2L1 plays an important role in haema-
topoiesis as it was shown that Bcl2L1 knockout mice die at stage E13 of embryonic develop-
ment because of cell death in immature neuronal and hematopoietic cells [71].  
The half-life of Bcl-xL mRNA is relatively short and the expression Bcl-xL protein is syn-
chronously with the Bcl-xL transcript [72]. So far it is known that Bcl2L1 contains two dis-
tinct regions with promoter activity placed upstream of the first coding exon (exon 2) and up-
stream of the first non-coding exon (exon 1) [73]. Hitherto, it is assumed that both regions are 
major transcription sites that differ in usage according to cell type and status of differentiation 
[73]. There are several transcription factors that are involved in the activation of Bcl2L1 in-
cluding Ets, Rel/NFκB, AP-1 and STAT (Figure 2.5) [72].  
 
 
Figure 2.5: The structure of the 5´regulatory sequence of human Bcl2L1.  
Shown are the predicted binding sites for the transcription factor complexes Ets, NFκB, STAT and AP-1. The 
consensus motifs, TATA box, exons and major transcription initiator site (+1) are pictured. Referring to Sevilla 
et al. [72]. 
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The dimeric transcription factor complex AP-1 (activator protein 1) consists of proteins that 
among others are members of the Jun (e.g. cJun and JunD) and Fos (f.e. cFos) family [74]. 
Sevilla et al. were able to show that Bcl2L1 was transactivated by c-Fos and c-Jun via the AP-
1 transcription factor binding site suggesting a critical role for these proteins in regulating 
Bcl-xL gene expression [75]. The signal transducer and activator of transcription (STAT) pro-
teins are subsequently activated after phosphorylation by JAKs that are downstream effectors 
of growth factors or cytokines [76]. Activated STATs are found in several tumors and con-
tribute to oncogenesis by affecting Bcl-xL. Thereby it was observed that the constitutive acti-
vation of STAT3 correlates with increased Bcl-xL level in squamous cell carcinoma of the 
head and neck [77]. In addition, STAT5 also seems to be able to induce Bcl-xL gene expres-
sion which was shown to be important for leukemic cell lines expressing Bcr-Abl [78]. Addi-
tionally, it has been shown that Bcl-xL is up regulated in several cancers including breast, 
prostate, pancreatic and colorectal cancer which is associated with poor prognosis [76].  
Besides the regulation of Bcl-xL gene expression, which is mediated by distinct transcription 
factor binding sites, it was recently shown that Bcl-xL mRNA is also a target for miRNAs. 
Shimizu et al. have observed that the miRNA let-7 inhibits Bcl-xL gene expression in human 
hepatocellular carcinoma and that less let-7 miRNA conferred a survival advantage to tumor 
cells [79]. In this study the miRNA let-7c and miRNA let-7g directly bind to the 3´-
untranslated region of the Bcl-xL mRNA. Therefore an absence of let-7 miRNA is associated 
with Bcl-xL overexpression [79]. Interestingly, Bcl-xL overexpression seems to be involved 
in increased metastatic ability as well. It has been demonstrated that transfection of the human 
breast cancer cell line MDA-MB-435 with Bcl-xL cDNA results in survival advantage ac-
companied by increased metastatic activity [80]. Concomitant with these findings are results 
showing that the overexpression of Bcl-xL in MCF-7 human breast cancer cell lines results in 
the prominent inhibition of apoptosis in response to several chemotherapeutics. Even though 
these experiments were additionally done with Bcl-2-over-expressing MCF-7 cells, Bcl-xL 
seems to exhibit a higher potential to inhibit apoptosis [81].  
2.4 Epithelial Mesenchymal Transition 
Epithelial Mesenchymal Transition (EMT) is a process whereby cells change their epithelial 
morphology into a fibroblast like phenotype (Figure 2.6). EMT is involved in numerous de-
velopmental processes including the mesoderm and neural tube formation [82]. However, 
EMT is also found in association with metastasis [83]. It is assumed, that during carcinogene-
sis some cells at the periphery of the primary tumor undergo EMT, whereby the cells acquire 
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mesenchymal properties. This mesenchymal state facilitates the invasion of cancer cells into 
local and distant tissues [83]. As a consequence of EMT, cells lose cell specific epithelial 
marker such as Occludin, Cytokeratin and as a hallmark of EMT, E-Cadherin. E-Cadherin 
functions as a tumor suppressor through the prevention of invasion and metastasis. During 
EMT E-Cadherin is repressed and degraded [84]. Instead of epithelial markers cells express 
mesenchymal markers including Vimentin, Fibronectin and N-Cadherin [85]. Due to the loss 
of cell polarity, these cells are able to survive without cell-cell contacts, which is important 
for the metastasis process [83].  
 
 
Figure 2.6: Epithelial Mesenchymal Transition (EMT).  
Cells that undergo EMT lose their epithelial phenotype and epithelial markers such as E-Cadherin, Occludin and 
Cytoceratin. Instead the cells acquire a mesenchymal cell shape and express mesenchymal markers including 
Vimentin, Fibronectin and N-Cadherin. Referring to Thiery et al. [85]. 
2.4.1 Regulation of EMT 
There are several mechanisms which are involved in initiating and executing EMT (Figure 
2.7). In cancer cells, the TGFβ signalling pathway activates multiple EMT-inducing transcrip-
tion factors, such as Slug, Zeb2 and Goosecoid via Smad activation [82]. Furthermore, the 
highly conserved canonical Wnt-signalling pathway is involved in initiating EMT [84]. In the 
inactive state of the Wnt-signalling pathway, β-Catenin complexes with APC and axin, which 
results in phosphorylation by GSK3β and degradation of β-Catenin by the proteasome [84]. 
But the active Wnt-signalling pathway and the loss of E-Cadherin from the adherens junctions 
results in the activation of β-Catenin, which in turn induces the EMT-inducing transcription 
factors Slug and Twist [82]. Additionally, the multiple tyrosine kinase receptor (TRK) path-
ways which involve FGFR, EGFR and HGFR activate the gene expression of Slug and Snail 
through the RAS-MAP kinase pathway [82]. Considering the regulation of E-Cadherin, the 
transcription factors Snail, Slug and Zeb2 suppress E-Cadherin transcription directly by bind-
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ing to the E-box motifs within the E-Cadherin promoter region. In contrast, Twist, Goosecoid 
and FOXC2 operate indirectly [82; 84].  
 
 
Figure 2.7: Signaling pathways involved in regulation of EMT.  
The TGFβ signalling pathways induce multiple EMT-inducing transcription factors in cancer cells such as Slug, 
Zeb2 and Goosecoid by the activation of Smads. Activation of the Wnt pathway and loss of E-Cadherin results 
in the activation of β-Catenin and subsequently in the activation of distinct EMT-transcription factors including 
Slug, Twist1 and Goosecoid. Multiple tyrosine kinase receptor (TRK) pathways induce the expression of Snail 
and Slug via the Ras-MAP kinase pathway. Solid lines indicate direct transcriptional or posttranscriptional regu-
lations. Dashed lines indicate indirect regulation. Referring to Yang et al. [82]. 
Besides regulation by distinct signalling pathways, it has been shown that EMT is also under 
the control of micro RNAs (miR). Gregory et al. were able to define five members of the 
miR-200 family which were specifically down regulated in cells that have undergone EMT, 
particularly miR-200a, miR-200b, miR-200c, miR-141 and miR-429 [86]. The expression of 
these miRNAs was diminished in invasive breast cancer cell lines displaying a mesenchymal 
cell shape. Consistent with these results, the ectopic expression of these miRNAs in mesen-
chymal cells results in Mesenchymal Epithelial Transition (MET) [86]. The most prominent 
targets of these miR-200 family members are Zeb1 and Zeb2 [87]. The transcription factors 
Zeb1 and Zeb2 act thereby as repressors for E-Cadherin, mediated by their binding to the E-
box motif in the proximal E-Cadherin promoter. As mentioned above, both factors are able to 
induce EMT and are involved in the TGFβ signalling pathways through binding to Smad co-
activators [88]. Interestingly, the miR-200 and Zeb interaction occurs in an inverse manner 
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[87]. Correspondingly, the knock down of Zeb1 results in an increase in the expression of all 
miR-200 family members [89]. Brabletz et al. therefore proposed a double-negative feedback 
loop between Zeb and miR-200 (Figure 2.8) [87]. Zeb transcription factors are strong EMT 
inducers, but the overexpression of miR-200 would result in decreased Zeb levels and epithe-
lial differentiation. However, depending on extracellular signals, the direction of this loop can 




Figure 2.8: Double-negative feedback loop of miR-200 and Zeb during EMT.  
miR-200 assisted E-Cadherin gene expression and epithelial morphology by post-transcriptional repression of 
the transcription factors Zeb1, Zeb2 and of TGFβ. During EMT Zeb1 and Zeb2 are induced by the active TGFβ 
signalling pathway, which results in E-Cadherin repression and is associated with a mesenchymal phenotype. 
This status is mediated by Zeb1/Zeb2 repression of miR-200 transcription in a double-negative feedback loop. 
This process is reversible with increased expression of miR-200, which induces MET by renewed induction of 
E-Cadherin gene expression accompanied by an epithelial cell shape. Adopted from Teague et al. [90]. 
2.4.2 EMT and cancer 
The molecular links between EMT transcription factors and self-renewal suggest that EMT 
plays a pivotal role in the early and late stages of the metastasis cascade [91]. Currently, 90% 
of tumors originate from epithelial tissue. However, the most apparent indicator differentiat-
ing a malignant and metastatic tumor from a benign one is the morphological change from an 
epithelial morphology to a mesenchymal invasive phenotype [92]. Nevertheless, the occur-
rence of Epithelial Mesenchymal Transition (EMT) in the progression of epithelial cancers in-
to disseminated metastasis is highly controversial. Actually, epithelial markers, such as cy-
tokeratins, are clinically used to characterize metastatic epithelial tumors in patients [92]. 
However, importantly not all steps that occur during the developmental process of EMT are 
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necessary to establish a metastatic phenotype, meaning that in vivo a partially dedifferentiated 
cell with a migratory and invasive phenotype should be expected to characterize metastasis 
[93]. The difficulty with this question is to demonstrate the importance of EMT during metas-
tasis in human cancer progression and the identification of cells that have undergone the EMT 
in primary human cancer samples. Currently used EMT markers are either expressed in epi-
thelial or in mesenchymal cells, but these markers are not specific enough to identify tumor 
cells at the EMT stage [82]. Hitherto, it is suggested that EMT in cancer progression depends 
on the tumor type, and moreover, it is assumed that EMT occurs locally at the invasive front 
of the primary tumor [93; 94]. Additionally, it has been recently proposed that EMT-like phe-
notypes can be classified based on their cell-cell adhesion status. The most prominent exam-
ples of tumors that complete EMT in vivo are the carcinosarcomas or metaplastic carcinomas, 
which represent fewer than 1% of invasive breast carcinomas, associated with poor prognosis 
[93]. Based on the expression of cytokeratins or Vimentin, these tumors can be distinguished 
in epithelial and mesenchymal compartments, respectively [93]. Even luminal A breast can-
cer, which typically displays an epithelial phenotype, can progress into metastasis including 
the process of EMT [95]. It is assumed that a subpopulation of cancer cells lose their epitheli-
al properties, while gaining the motile and invasive behavior of mesenchymal cancer cells 
[95]. More direct evidence for EMT in breast cancer was supplied by Trimboli et al. by de-
veloping stromal- and epithelial-specific mouse models that can be used to directly visualize 
EMT in cancer progression in vivo [96]. Thus, they were able to genetically mark mammary 
epithelial and stromal cells and follow their fate, while tumors developed in vivo [96].  
Furthermore, transcription factors that are involved in the EMT process are transcriptional 
suppressors, that can partially direct repress epithelial adhesion molecules [91]. Slug, Zeb1 
and Twist for example, repress E-Cadherin gene expression, an integral component of ad-
herens junctions. Additionally, the gene expression of the molecule claudin, which is involved 
in the assembly of tight junctions between adjacent cells is repressed by Snail and Slug [91]. 
Due to the up-regulation of the mesenchymal marker N-Cadherin, Vimentin and Fibronectin, 
cells acquire a front-to-back polarization, which in the end results in their ability to migrate 
and invade surrounding tissues as single cells. Together, the molecular changes of disseminat-
ing cancer cells complete the early steps of the metastatic cascade. Hence, EMT presents a 
possible explanation as to how cancer cells acquire the ability to invade surrounding tissues, 
survive systemic dissemination and extravasation into distant regions of the organism [91]. 
The increased levels of several EMT transcription factors seem to be an attribute of several 
cancers. Twist e.g. is expressed in invasive lobular breast carcinoma, a highly infiltrating tu-
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mor type that exhibits loss of E-Cadherin. Thus, the suppression of Twist in cancer cells is ac-
companied by an decrease of their metastatic potential in vivo [97].  
Invasive breast cancer comprises phenotypically diverse populations of tumor cells, which is 
reflected in tumor histology, clinical presentation and response to therapy [93]. Al-Hajj et al. 
observed a minor cell population within human breast cancer samples that contain the ability 
to form new tumors [98]. Based on their cell surface marker expression, tumorigenic and non-











 cells (referred as CD24
+
), respectively. Indeed, is has been demonstrated that 
CD44
+
 cells from breast cancer patients were more tumorigenic in NOD/SCID mice than 
CD24
+
 cells, whereby the resulting xenografts reproduce the heterogeneity of the original tu-
mors [98]. Beyond this, Shipitsin et al. identified that the CD44
+
-cell specific gene expression 
profile within these heterogeneous breast cancer tissues resembles that of stem cells, normal 
and CD44
+
-tumor cells, more than CD24
+
 cells from the same tissue [99]. Moreover, they 
have shown that the TGFβ signalling pathways, which are also involved in inducing EMT, are 
specifically active in CD44
+
 tumor cells, concomitant with a mesenchymal phenotype. Thus, 
treatment with a TGFβ-inhibitor resulted in dramatic morphological changes in CD44
+
 tumor 
cells, accompanied by the acquisition of an epithelial phenotype of these cells within 24h 
[99]. Due to this heterogeneity, it is assumed that a process like EMT contributes to cancer 
progression, but depends on the tumor type [93]. 
2.4.3 EMT involved in chemoresistance 
Tumors that have undergone EMT may acquire resistance to chemotherapy. Correspondingly, 
epithelial colon carcinoma cell lines that are resistant to Oxaliplatin exhibit mesenchymal 
properties and express distinct markers for EMT [100]. Moreover, chemoresistance to 
Paclitaxel in ovarian cancer cells lines was observed to be associated with the expression of 
EMT markers and loss of epithelial phenotype [101]. Furthermore, highly invasive subpopu-
lations of MCF-7 and MDA-MB-434 cells that have undergone EMT, displayed increased 
levels of Twist and its target gene Akt2, which was also associated with Paclitaxel resistance 
[102]. Consistent with these results, it was observed that the reduction of Twist in breast can-
cer cells results in a partial reverse of the acquired multi drug resistance [85; 103]. Similarly, 
the suppression of Twist in lung cancer cell line A549 results in sensitivity towards Cisplatin 
[104].  
Moreover, in post-treatment biopsies of patients with breast cancers that were medicated with 




 cells was observed which 
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 surface profile as well and can be regulated by EMT transcription factors [91]. 
It has been shown that these stem cell like cancer cells express increased level of ABC-
transporter and multi-drug-resistant proteins, protecting them from chemotherapeutic treat-




 cells contain more active al-
dehyde dehydrogenase 1 (ALDH 1) which constitutes a detoxifying enzyme that oxidizes in-
tracellular aldehydes and induces resistance to alkylating agents [106; 107; 108]. Finally, the 
inhibition of apoptosis is a crucial mechanism to escape chemotherapy. Thereby, Twist has 
been shown to inhibit apoptosis by several mechanisms. These mechanisms include the inhi-
bition of the pro-apoptotic properties of the Myc oncogene, the activation of the NFκB signal-
ling pathway and through the repression of p53-induced pro-apoptotic genes [91].  
2.4.4 Model system for EMT 
Weinberg and colleagues (MIT Boston, USA) have established a model system for EMT con-
taining the Human Mammary Large T-antigen immortalized Epithelial cells, named HMLE 
(Figure 2.9) [109]. To create this model system, primary Human Mammary Epithelial Cells 
(HMEC) from reduction mammoplasty tissue samples from a healthy female donor were im-
mortalized using the SV-40 large T antigen of the simian virus 40 and the subunit of the hu-
man telomerase hTERT. Thereby, hTERT maintains the telomeres during the cell cycle, while 
the SV-40 large T antigen is involved in the inactivation of the p53 and pRB pathways [109]. 
Upon this immortalization it is possible to culture these cells. However, to work with a model 
system that is more cancer-orientated and is indeed able to induce tumors, these HMLEs were 
additionally transformed with the oncogene haRAS and thus acquire a constitutive mitogenic 
signal [109]. The EMT model system predominantly used in this thesis is HMLE RAS: Hu-
man Mammary Large T-Antigen immortalized Epithelial HaRas expressing cells.  
 
 
Figure 2.9: Stepwise transformation of HMECs to create the HMLE RAS model system.  
Initially, HMECs were immortalized with the SV40 large T antigen and the telomerase subunit hTERT to obtain 
the HMLEs. Further, HMLE cells were transformed with the haRAS oncogene to receive tumorigen HMLE 
RAS cells.  
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RAS cells, respectively, which display an epithelial phenotype and are typ-




RAS cells are not able to 
induce tumors, which is a characteristic of cells before EMT. However, it is possible to isolate 




RAS cells termed Mesenchymal subpopulation 
(MSP) that express mesenchymal markers such as Vimentin and N-Cadherin and are accom-
panied by a mesenchymal morphology. MSP and MSP RAS cells, respectively, are positive 
for CD44, able to migrate and are typical of cells that have undergone the process of EMT. 
Additionally, Weinberg and colleagues have shown that MSP RAS in contrast to 24
+
 RAS are 
highly invasive and tumorigenic [110]. 
Scheel et al. have shown that MSP cells remain stable in the mesenchymal state and that the 
induction of EMT and subsequent maintenance of the mesenchymal state occurs spontaneous-
ly and is not generated by an experimental procedure [110]. Additionally, they observed that 
MSP cells express less Wnt-repressors such as DKK1 and sFRP than their parental counter-
part, the 24
+
HMLE cells. Consistent with this, the MSP cells express the non-canonical Wnt 
ligands Wnt5a and Wnt16. Moreover, Scheel et al. found activation of the canonical Wnt 
pathway in MSP cells as well. At this they were able to determine active TOPFlash Luciferase 
reporter assays, indicating that this pivotal EMT signalling pathway is highly induced in MSP 
cells [110].  
 
 
Figure 2.10: HMLE RAS cells as model system for EMT.  
24
+
HMLE Ras display an epithelial morphology, are highly positive for the surface marker CD24, lack efficient 
migration and express E-Cadherin. 24
+
HMLE Ras show characteristics of cells before EMT. MSP Ras exhibit a 
mesenchymal phenotype and express the mesenchymal markers Vimentin and N-Cadherin. MSP Ras are highly 
invasive and express the surface marker CD44 but not CD24. MSP Ras cells show characteristics of cells that 
have undergone EMT and contain a highly active Wnt-signalling pathway.  
Mani et al. have shown, that EMT induced by the overexpression of the transcription factor 
Twist in immortalized human mammary epithelial cells (HMLE), not only results in the ac-
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quisition of a mesenchymal phenotype, but rather results in the expression of stem cell mark-




 cells within the mes-
enchymal population, which displayed the ability to form mammospheres, an attribute that is 
concomitant with stem cells. Indeed, HMLEs that underwent EMT by ectopic expression of 
Twist formed 30-fold more mammospheres than HMLEs infected with the control vector 
[111]. These findings by Mani et al. strongly imply that the MSP and MSP RAS cells used in 
our EMT system obtain these stem cell markers as well. 
2.5 Objective 
As described in detail above, a major problem in treating cancer is the acquisition of chemo-
resistance by cancer cells. It was recently published, that tumor cells that survive chemothera-
py differ from the major tumor population and contain tumor initiating properties that are as-
sociated with resistance to chemotherapy [4]. New knowledge of this subpopulation revealed 
disseminating cells that change their behaviour and morphology during the process of EMT. 
These cells acquire the ability to invade local and distant tissues, form metastasis and escape 
chemotherapeutic treatment. Considering the various ways in which tumor cells can manipu-
late their chemoresponse, the question arises as to how these cells acquire chemoresistance 
and how EMT comes into play. What differs in cells upon EMT in comparison to their paren-
tal cells? 
To investigate how EMT affects the response to chemotherapy, we were provided with a 
model system for EMT containing the Human Mammary Large T-Antigen immortalized Epi-
thelial HaRas expressing cells (HMLE RAS) by Weinberg and colleagues (MIT Boston, 
USA). This model system is composed of two different cell lines. On the one hand are the pa-
rental 24
+
 RAS cells that display an epithelial morphology and lack efficient migration. On 
the other hand are the MSP RAS cells (mesenchymal subpopulation) that originate from the 
24
+
 RAS cells. MSP RAS cells contain activated EMT signalling pathways accompanied by a 
mesenchymal cell shape and high invasivity. Preliminary experiments have confirmed that 
these cells are resistant to several chemotherapeutics and encouraged us to determine how 
these cells became chemoresistant during the process of EMT and which mechanism is be-
hind it. We wanted to figure out the level at which the resistance mechanism occurs and 
moreover, we were interested in overcoming resistance in cells upon EMT. The correlation of 
EMT, tumor-initiating cells and chemotherapeutic resistance is a recent field in carcinogene-
sis. Understanding the mechanisms that are involved in chemoresistance regarding EMT is 
most important to develop novel therapeutic approaches to medicate cancer.  




Figure 2.11: Objective at a glance.  
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3. Material  
3.1 Technical devices 
Table 3.1: Technical devices 
Device Company 
Blotting chamber  Biozym, Hessisch Oldendorf, Germany 
Cell counting chamber Neubauer improved Brand, Wertheim, Germany 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf 
Centrifuge Megafuge 1.0R Heraeus, Thermo Scientific, Waltham, MA, 
United States 
Chemiluminescence imager Chemocam HR 
16 3200 
Intas Science Imaging Instruments, Göttin-
gen, Germany 
Cytometer Celigo Cyntellect, San Diego, CA, United States 
DNA gel chamber Biotech Service Blu, Schauenburg, Germany 
Electrophoresis system, for SDS-PAGE Amersham Biosciences, GE Healthcare, Lit-
tle Chalfont, United Kingdom 
FACS machine Guava PCA-96 Base System Millipore, Merck, Darmstadt, Germany 
Foil swelding machine Vacupack plus Krups, Groupe SEB, Lyon, France 
Freezer -20°C Liebherr, Bulle, Switzerland 
Freezer -80°C Heraeus, Thermo Scientific 
Heating Block Grant Instruments, Hillsborough, NJ, United 
States 
Heating Block HLC HLC Biotech, Ditabis, Pforzheim, Germany 
Ice-machine B100 Ziegra, Isernhagen, Germany 
Incubator for bacteria Memmert, Schwabach, Germany 
Incubator for bacteria Minitron Infors HT, Basel, Switzerland  
Laminar flow cabinet Hera Safe Heraeus, Thermo Scientific 
Liquid nitrogen tank LS 4800 Taylor-Wharton, Theodore, AL, United 
States 
Magnetic stirrer MR Hei-Standard Heidolph, Schwabach, Germany 
Magnetic stirrer MR3001 Heidolph 
Microscope Axovert 40C Zeiss, Oberkochen, Germany 
Microscope, Axioscope 2 Plus Zeiss 
Microscope, confocal Zeiss Confocal LSM 
510 meta 
Zeiss 
Microwave  Cinex, Lippstadt, Germany 
Mini Centrifuge MCF-2360 LMS, Tokyo, Japan 
PCR machine for qRT-PCR Chromo4 Bio-Rad Laboratories 
PCR machine Thermocycler T personal Biometra, Göttingen, Germany 
pH-meter WTW-720 WTW, Weilheim, Germany 
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Pipet Multipette Eppendorf 
Pipet, electric Portable-XP Drummond, Broomal, PA, United States 
Pipets Eppendorf Research Series 2100 
(0.1-2.5μl; 0.5-10μl; 10-100μl; 100-1000μl) 
Eppendorf 
Pipette, multichannel Research Plus Eppendorf 
Power supply unit Powerpack P25T Biometra 
Refrigerator 4°C Liebherr 
Roller RM5 V-30 CAT, Staufen, Germany 
Rotator PTR 300 Grant Instruments 
Scales Acculab ALC-6100.1 Sartorius, Göttingen, Germany 
Scales LE623S Sartorius 
Scanner CanoScan 8600F Canon, Tokyo, Japan 
Sequencer, automated ABI 3100 Applied Biosystems, Life Technologies 
Shaker PROMAX 2020 Heidolph 
Sonication device Bioruptor Diagenode, Liège, Belgium 
Spectrophotometer NanoDrop ND-1000 PeqLab, Erlangen, Germany 
Thermomixer comfort Eppendorf 
Vacuum pump IBS Integra Biosciences, Fernwald, Germany 
Vortex Genie 2 Scientific Industries, Bohemia, NY, United 
States 
Water bath TW 20 Julabo Labortechnik, Seelbach, Germany 
 
3.2 Consumables 
Table 3.2: Consumables 
Product Company 
12-well plates for microscopy Corning, Corning, NY, United States 
96-well plates for qPCR 4titude, Wotton, United Kingdom 
Cell culture flasks (25cm², 75cm²,125cm²) Greiner, Frickenhausen, Germany 
Cell culture plates (6-well, 12-well) Greiner 
Cell scraper (16cm, 25cm) Sarstedt 
Cryo tubes Cryoline Nunc, Thermo Scientific 
Filter tips (10µl) Starlab, Hamburg, Germany 
Filter tips (20µl, 200µl, 1,000µl) Sarstedt 
Parafilm Brand 
Pipet tips (10µl, 20-200µl, 1,000µl) Greiner 
Protran nitrocellulose transfer membrane Whatman, Dassel, Germany 
Reaction tube (0.2ml) Sarstedt 
Reaction tube (0.5ml, 1.5ml, 2.0ml) Eppendorf 
Reaction tube (15ml, 50ml) Greiner 
Safe-lock reaction tube (1.5ml) Eppendorf 
Sterile filter Millipore, Merck 
Syringe Henke-Sass, Wolf, Tuttlingen, Germany 
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Syringe canula (different sizes) B.Braun, Melsungen, Germany 
Transparent sealing foil for 96-well plate 4titude 
Whatman paper Whatman 
3.3 Chemicals and reagents 
Table 3.3: Chemicals and reagents 
Substance Company 
Acetic acid Roth, Karlsruhe, Germany 
Acrylamide-bisacrylamide Roth 
Albumin Fraction V (Bovine Serum Albumine, 
BSA) 
Roth 
Ammonium persulfate (APS) Roth 
Ammonium sulfate ((NH4)2SO4) Roth 
Aprotinin Applichem 
Bromophenol blue Sigma-Aldrich 
Calcium chloride dihydrate (CaCl2 x 2H2O) Roth 
Chloroform Roth 
Crystal violet Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) AppliChem 
Dithiotreitol (DTT) Sigma-Aldrich 
DNA ladder Fermentas, Thermo Scientific 
Deoxynucleotide triphosphates (dNTPs) Bio-Budget, Krefeld, Germany 
Ethanol 99.8% Roth 
Ethanol 99.9% p.a. (EtOH) Merck 
Ethylene diamine tetraacetatic acid (EDTA) Roth 
Ethylene glycol tetraacetic acid (EGTA) Roth 
FCS Thermo Scientific HyClone 
Glycerol Roth 
Glycine Roth 
Glycogen Fermentas, Thermo Scientific 
Glycogen blue Ambion, Life Technologies 
Guava ICF Cleaning Solution Millipore, Merck 
Guava Viacount reagent Millipore, Merck 
HEPES Roth 
Hydrogen chloride (HCl) Roth 
Immersion oil Zeiss 
Isoamyl alcohol Roth 
Isofluran Baxter 
Isopropanol Th. Geyer, Renningen, Germany 
Leupeptin Hemisulfat Applichem 
Lipofectamine 2000 Invitrogen, Life Technologies 
Magnesium chloride (MgCl2) for PCR Fermentas, Thermo Scientific 
Magnesium chloride hexahydrate (MgCl2 x Roth 
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6H2O) 
Matrigel™ Basement Membrane Matrix BD Biosciences 
Methanol >99% (MetOH) Roth 
Microcystin-LR JenaBioscience 
Milk powder Roth 
Nonidet P-40 substitute (NP-40) Sigma Aldrich 
Nuclease free water Ambion, Life Technologies 
Pefabloc SC  Roth 
Pepstatin A Applichem 
Ponceau S Roth 
Potassium chloride (KCl) Roth 
Potassium glutamate (KGlu) Roth 
Potassium hydrogenphosphate (KH2PO4) Roth 
Prestained Protein Ladder Fermentas, Thermo Scientific 
RNase inhibitor Fermentas, Thermo Scientific 
Rotiphorese Gel 30 Roth 
Sodium acetate (NaAc) Roth 
Sodium bicarbonate (NaHCO3) Roth 
Sodium chloride (NaCl) Roth 
Sodium deoxycholate Applichem 
Sodium dodecyl sulfate (SDS) Roth 
Sodium hydrogenphosphate heptahydrate 
(Na2HPO4 x 7H2O) 
Roth 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Sodium orthovanadate Sigma-Aldrich 
SYBR green Invitrogen, Life Technologies 
Tetracycline Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Roth 
Trasylol Bayer, Leverkusen, Germany 
Trehalose Sigma-Aldrich 
Trisamine (Tris) Roth 
Triton X-100 Applichem 
Trizol Invitrogen, Life Technologies 
Tween 20 Applichem 
β-Mercaptoethanol Roth 
 
3.3.1 Buffers and solutions 
 
Table 3.4: Buffers and solutions 
Buffer / Solution Components 
BSA solution 5% BSA 
dissolved in TBS/T 
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Cell lysis buffer 100% Ripa lysis buffer 
2M Urea 
1µg/ml Aprotinin 
1µg/ml Leupeptin Hemisulfat 
1µg/ml Pepstatin A 
1mM Pefabloc SC 
0.5µg/ml Microcystin 
 




0.02% Bromphenol blue 
 dissolved in H2O 
  
PBS, pH 7.4 24mM NaCl 
0.27mM KCl 
0.81mM Na2HPO4 x 7H2O 
0.15mM KH2PO4  
dissolved in H2O 
  
TBS/T, pH 7.5 50mM Tris 
150mM NaCl 
0.1% Tween 20 
dissolved in H2O 
  
qRT-PCR reaction buffer, 10x 750mM Tris-HCl, pH 8.5 
200mM (NH4)2SO4 
0.1% Tween 20 
 dissolved in H2O 
  
qRT-PCR reaction mix, 25x 1x qRT-PCR reaction buffer 10x 
3mM MgCl2 
1:80.000 SYBR Green 
0.2mM dNTPs 
20U/ml Taq polymerase 
0.25% Triton X-100 
300mM Trehalose in 10mM Tris, pH 8.5 
dissolved in water 
  
Ripa lysis buffer, pH 7.5 1% Triton X-100 
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20mM Tris, pH 7.5 
50.000KIU Trasylol 
dissolved in H2O 
  
SDS running buffer 25mM Tris 
86.1mM Glycin 
3.5mM SDS 
dissolved in H2O 
  
Western blot blocking solution 5% milk powder 
dissolved in TBS/T 
  
Western salts, pH 8.3 0.25M Tris, pH 8.3 
0.19M Glycin 
0.02% SDS 
dissolved in H2O 
  
Western blot transfer buffer 1x Western salts 10x 
20% MeOH 
dissolved in H2O 
 
3.3.2 Chemotherapeutics and pharmological inhibitors 
Table 3.5: Chemotherapeutics 
Chemotherapeutic Commercial name Company 
Carboplatin  Carbomedac® medac Gesellschaft für klinische 
Spezialpräparate mbH 
Cisplatin Cisplatin KL Neocorp AG, Weilheim 
Doxorubicin - Santa Cruz 
Neocarcinostatin - Sigma Aldrich 
 




Akt inhibitor LY294002 Akt Cell Signaling 
Bcl-xL inhibitor Gossypol Bcl-xL Selleckchem 
CHX Cycloheximide A-site of ribosomes Sigma Aldrich 
HSP90 inhibitor 17AAG HSP90 NCI 
HSP90 inhibitor 17DMAG HSP90 NCI 
JNK inhibitor SB600125 JNK Sigma Aldrich 
Mek1 inhibitor U0126 Mek1 Cell Signaling 
MG132 Z-Leu-Leu-Leu-al proteasome Sigma Aldrich 
mTOR inhibitor Rapamycin mTOR Calbiochem 
p38 inhibitor SB203580  p38 Biomol 
TGFβ inhibitor SB431542 TGFβ Sigma Aldrich 
3 Material  32 
3.3.3 Enzymes and proteins 
Table 3.7: Enzymes and proteins 
Reagent Company 
M-MuLV Reverse transcriptase (RT) New England Biolabs 
Rnase inhibitor New England Biolabs 
Taq DNA polymerase (Taq) Primetech LTD, Minsk, Belarus 
TNFα (in sterile H2O) Gibco 
Trail (in sterile H2O) Gibco 
3.4 Kits 
Table 3.8: Kits 
Name Company 
BCA Protein Assay Kit Thermo Scientific 
Guava Check Kit Millipore, Merck 
Guava® Multi Caspase FAM Kit Millipore, Merck 
Immobilon Western HRP Substrate Peroxide 
Solution  
Millipore, Merck 
NucleoBond® AXG Mecherey Nagel 
SuperSignal West Femto Maximum Sensitivity 
Substrate 
Thermo Scientific 
TaqMan® MicroRNA Assay Invitrogen 
3.5 Oligonucleotides 
Table 3.9: Small interfering RNAs 
Target siRNA ID Sequence 
Negative control No.2 - undisclosed 
Bcl-xL #1 s1920 sense: 5´-AUACUUUUGUGGAACUCUAtt-3´ 
antisense: 5´-UAGAGUUCCACAAAAGUAUcc-3´ 
Bcl-xL #2 s1921 sense: 5´-GCUGGAGUCAGUUUAGUGAtt-3´ 
antisense: 5´-UCACUAAACUGACUCCAGCtg-3´ 
Bcl-xL #3 s1922 sense: 5´-GGAACUCUAUGGGAACAAUtt-3´ 
antisense: 5´-AUUGUUCCCAUAGAGUUCCac-3´ 
cFos #1 s5339 sense: 5´-CACUCCAAGCGGAGACAGAtt-3 
antisense: 5´-UCUGUCUCCGCUUGGAGUGta-3´ 
cFos #2 s5340 sense: 5´-CUUCCUUCGUCUUCACCUAtt-3´ 
antisense: 5´-UAGGUGAAGACGAAGGAAGac-3´ 
cJun #1 s7658 sense: 5´-GGCACAGCUUAAACAGAAAtt-3´ 
antisense: 5´-UUUCUGUUUAAGCUGUGCCac-3´ 
cJun #2 s7659 sense: 5´-CCAAGUGCCGAAAAAGGAAtt-3´ 
antisense: 5´-UUCCUUUUUCGGCAUUGGag-3´ 
cJun #3 s7660 sense: 5´-GGAUCAAGGCGGGAGAGGAAtt-3´ 
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antisense: 5´-UUCCUCUCCGCCUUGAUCCgc-3´ 
HSP90α s6994 sense: 5´-CUAUGGGUCGGUGGAACAAAtt-3´ 
antisense: 5´-UUUGUUCCACGACCCAUAGgt-3 
HSP90β s6999 sense: 5´-GGAUGACAGCGGUAAGGAUtt-3´ 
antisense: 5´-AUCCUUACCGCUGUCAUCCtc-3´ 
JunD #1 s7664 sense: 5´-GUUUCUACUCGGGAACAAAtt-3´ 
antisense: 5´-UUUGUUCCCGAGUAGAAACat-3´ 
JunD #2 s7665 sense: 5´-UCCACAUUCCUGUUUGUAAtt-3´ 
antisense: 5´-UUACAAACAGGAAUGUGGAct-3´ 
Dicer #1 s23754 sense: 5´-GAUCCUAUGUUCAAUCUAAtt-3´ 
antisense: 5´-UUAGAUUGAACAUAGGAUCga-3´ 
Dicer #2 s23755 sense: 5´-CAGCAUACUUUAUCGCCUUtt-3´ 
antisense: 5´-AAGGCGAUAAAGUAUGCUGgg-3´ 
 
All siRNA are silencer select from Ambion® Life Technologies.  
 
Table 3.10: Primer 
Name Sequence 
Axin2 for 5´-TCCCCACCTTGAATGAAGAA-3´ 
rev 5´-TGGTGGCTGGTGCAAAGA-3´ 
Bcl2L1 for 5´-ACCGGCGGGCATTCAGTGAC-3´ 
rev 5´-TGAGCCCAGCAGAACCACGC-3 
Bcl-xL for 5´-CCTTTTTCTCCTTCGGCGGGGC-3´ 
rev 5´-GCCCTTTCGGCTCTCGGCTG-3´ 
Bcl-xS for 5´-AGAGCTTTGAACAGGATACTTTTGTGGA-3 
rev 5´-TGAGCCCAGCAGAACCACGC-3 
CD24 for 5´-ACCCAGCATCCTGCTAGACGCG-3´ 
rev 5´-AGTTGGATTTGGGGCCAACCCAGA-3´ 
cFos #1 for 5´-CTTACTACCACTCACCCGCAG-3´ 
rev 5´-GTGGGAATGAAGTTGGCACTG-3´ 
cFos #2 for 5´-CTACCACTCACCCGCAGAC-3 
rev 5´-GTCCGGACTGGTCGAGAT-3´ 
cJun  for 5´-CCCCAAGATCAACAGA-3´ 
rev 5´-CCGTTGCTGGGATTAT-3´ 
c-Myc for 5´-AGCCAGCGGTCCGCAACCCTTGCC-3´ 
rev 5´-AGCTCGAATTTCTTCCAGATATCC-3´ 
E-Cadherin for 5´-CCTGGACGCTCGGCCTGAAG-3´ 
rev 5´-ATAAGGCGGGGCTGTGGGGT-3´ 
HSP90 pan for 5´-CCCTTCCACGTCTCTGCATT-3´ 
rev 5´-CTAAACCTCCTCCTCCTCCA3´ 
JunD #1 for 5´-CCCCTTCGGTTCTTTCGACC-3´ 
rev 5´-CGGGCGAACCAAGGATTACA-3´ 
JunD #2 for 5´-CCCTCAAGAGTCAGAACACGG-3 
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rev 5´-GACGTGGCTGAGGACTTTCT-3´ 
MMP7 for 5´-GAGGAGCTCATGGGGACTC-3´ 
rev 5´-CCATAGGTTGGATACATCACTGC-3´ 
Twist for 5´-GGAGTCCGCAGTCTTACG-3´ 
rev 5´-TCTGGAGGACCTGGTAGAGG-3´ 
Vimentin for 5´-CGTGTATGCCACGCGCTCCT-3´ 
rev 5´-TCGAGCTCGGCCAGCAGGAT-3´ 
Zeb1 for 5´-GCGCAGAAAGCAGGCGAACCC-3´ 
rev 5´-CCCTTCCTTTCCTGTGTCATCCTCC-3´ 
Zeb2 for 5´-AACGGTCCTGCCTCCCGACA-3´ 
rev 5´-AGTTCGCATGGACTCGGCGC-3´ 
36B4 for 5´-GATTGGCTACCCAACTGTTG-3´ 
rev 5´-CAGGGGCAGCAGCCACAAA-3´ 
 
All primers are from Metabion.  
3.6 Antibodies 
Table 3.11: Primary Antibodies 
Name MW [kDa] Source Dilution Company (Cat.No.) 
β-Actin 42 mouse 
monoclonal 
1:100,000  Santa Cruz (sc-24) 
 
 
Akt 60 rabbit 
polyclonal 
1:1000 Cell Signaling (9272) 
     
Bcl-2  26 rabbit 
polyclonal 
1:1000 Cell Signaling (2870) 
     
Bcl-xL 30 rabbit 
polyclonal 
1:2000 Cell Signaling (2764) 
     
Bcl-xL 30 mouse 
monoclonal 
1:1000 Santa Cruz (sc-8392) 
     
Caspase 3 (cleaved) 17 / 19 rabbit 
polyclonal 
1:1000 Cell Signaling (9664) 
     
Caspase 3 (full) 35 rabbit 
polyclonal 
1:1000 Cell Signaling (9665) 
     
cJun 39 rabbit 
polyclonal 
1:1000 Abcam (ab32137) 
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Hif1α 120 rabbit 
polyclonal 
1:1000 
Cell Signaling (3716) 
     
Mcl-1 40 rabbit 
polyclonal 
1:1000 Cell Signaling (5453) 





1:1000 Cell Signaling (9271) 
     
P-cJun (Ser 63) 48 rabbit 
polyclonal 
1:500 Cell Signaling (9261) 
     
P-erk1 (Tyr 204) 44 mouse 
monoclonal 
1:500 Santa Cruz (sc-7383) 
     
P-JNK1/2 
(Thr 183 / Tyr 185) 
46 / 54 rabbit 
polyclonal 
1:500  Cell Signaling (4668S) 
     
P-S6 Kinase  
(Ser 235 / 236) 
32 rabbit 
polyclonal 
1:1000 Cell Signaling (2211) 
     
PARP 85 / 116 mouse 
monoclonal 
1:1000 Calbiochem (AM30) 
     
PARP 85 / 116 rabbit 
polyclonal 
1:2000 Cell Signaling (9542) 
     
 
 
Table 3.12: Secondary Antibodies 
Name Cat.No. Company 
HRP-coupled AffiniPure F(ab')2 
fragment, anti-mouse IgG (H+L) 
711-036-152 Jackson Immunoresearch, 
Europe, Newmarket, UK 
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3.7 Human cell culture 
Table 3.13: Human cell lines 

















 mesenchymal stably expressing 
Bcl-xL 
MSP  mesenchymal no selection 
required 
MSP RAS  mesenchymal selection with 
Blasticidin 
 
Table 3.14: Contents of MEGM medium for human cell culture (HMLE / HMLE RAS) 
Reagent Company Cat.No.  for 1l 
Blasticidin Sigma Aldrich 15205 5ng/ml 
DMEM High Glucose 
Phenol-Red Free 
Invitrogen 21063-045 250ml 
F-12 Nutrient Mixture 
(Ham), liquid 
Invitrogen 21765-029 250ml 
MEGM BulletKit  Lonza CC-3150 500ml MEGM 
0.004ml/ml BPE 
10ng/ml hEGF 
5µg/ml human hydrocortisone 
5µg/ml human insulin 
15µg/ml Gentamicin 
7.5ng/ml Amphotericin 
human EGF Sigma Aldrich E9644 500µl 
human Hydrocortisone Sigma Aldrich H0888 500µl 
human Insulin Sigma Aldrich I9278 500µl 
 
Table 3.15: Subculture reagents for human cell culture (HMLE / HMLE RAS) 
Reagent Company Cat.No.  
HEPES buffered Saline Lonza CC-5034 
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3.8 Mice 
Six week old female homozygous nude mice (Nu/Nu) were purchased from Janvier, Paris. 
Nude mice are laboratory mice with lacking a thymus, are unable to produce T-cells and are 
therefore immunodeficient. The genetic basis of these mice is a mutational disruption of the 
FOXN1 gene. All mice were kept in the animal facility of the Zentrale Tierexperimentelle 
Einrichtung at the University Medical Center Göttingen. Mice were handled according the re-
strictions of the German animal welfare act.  
3.9 Software 
Table 3.16: Software 
Name Company 
Adobe Photoshop CS5 Adobe Systems, San Jose, CA, United States 
AxioVision 3.0  Zeiss 
BioEdit v7.0.5  
 
Tom Hall, Ibis Therapeutics, Isis Pharmaceuti-
cals, Carlsbad, CA, United States 
CFX Manager Software 
for qPCR cycler  
Bio-Rad 
Excel Microsoft, Redmond, WA, United States 
GraphPad Prism® GraphPad Software, Inc., CA United States 
Guava Express Software  Millipore, Merck 
INTAS lab ID  Intas Science Imaging Instruments 
NanoDrop Software Peqlab 
Office Picture Manager Microsoft, Redmond, WA, United States 
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4. Methods 
4.1 Cell biology 
4.1.1 Culturing of human cells 
Adherent human cells were cultured in coated cell culture flasks with filter caps at 37°C, 
5%CO2 and a humidified atmosphere in MEGM media supplemented with 25% DMEM high 
glucose phenol red free, 25% F12 nutrient mixture, 0.004ml/ml BPE, 10ng/ml hEGF, 5µg/ml 
human hydrocortisone, 5µg/ml human insulin, 15µg/ml Gentamicin and 7.5ng/ml Amphoteri-
cin. For selection pressure and therefore preventing loss of the haRAS construct, culture me-
dium for the haRAS transformed cells was supplemented with 5ng/ml Blasticidin. For the 
subculture, cells were washed with HEPES buffered saline and detached by incubation with 
trypsin/EDTA at 37°C. Subsequently, the enzymatic reaction of trypsin was stopped by add-
ing Trypsin Neutralizing Solution (TNS). Afterwards, cells were centrifuged for 8min at 
900rcf and RT. The supernatant was aspirated and the cell pellet was dissolved in supple-
mented MEGM medium. The cells were reseeded at dilutions of 1:2.5 up to 1:5 every second 
day. For experiments, cell pellets were dissolved in Blasticidin-free medium, to have only one 
trigger during the cell treatments. The cell number was defined by counting with a Neubauer 
chamber and seeded at the respective density. All cell culture work was performed under ster-
ile conditions.  
 
4.1.2 Freezing of cells and thawing of frozen cells 
For long-term storage, cells in a low passage were detached from a 175cm²-size cell culture 
flask as described above. After centrifugation (8min, 900rcf, RT) the supernatant was aspired 
and the cell pellet was dissolved in 6ml cold FCS containing 10% DMSO. The suspension 
was aliquoted in four cryo vials and stored at -80°C for 24h before the vials were transferred 
into liquid nitrogen. For thawing of the cells, the aliquots were taken from storage in the liq-
uid nitrogen, were rapidly thawed and transferred into pre-warmed supplemented MEGM 
medium. Afterwards, the cells were centrifuged (8min, 900rcf, RT) and the pellets were re-
suspended in fresh pre-warmed medium. Subsequently, 24
+
HMLE (RAS, Bcl-xL) and MSP 
(RAS, Bcl-xL) cells were seeded into 25cm²- and 75cm²-size cell culture flasks, respectively. 
Medium was changed after 24h to remove dead cells.  
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4.1.3 Model system for EMT: HMLE and HMLE RAS cells 
4.1.3.1 Generating the HMLE and HMLE RAS system 
The model systems for Epithelial Mesenchymal Transition (EMT) consisting of 24
+
HMLE 
(Human Mammary Large T-antigen immortalized Epithelial cells) and MSP (Mesenchymal 
Subpopulation) cells as well as 24
+
 RAS and MSP RAS cells. We were kindly provided with 
these cells by Weinberg and colleagues (MIT Boston, USA). To create the model system for 
EMT, HMECs (Human Mammary Epithelial Cells) were obtained from reduction mammo-
plasty tissue samples from a healthy donor and were immortalized using retroviral transfec-
tion expressing the catalytic subunit of the human telomerase enzyme hTERT and the SV-40 
large T antigen. Thereby, hTERT ensures maintenance of the telomers, while the SV-40 large 
T antigen is involved in the inactivation of the p53 and pRB pathways. To generate tumor-
igenic HMLEs the cells were transformed with the haRAS oncogene acquiring a constitutive 
mitogenic signal [112].  
The Retroviral transfection was performed by Weinberg and colleagues (MIT Boston, USA) 
as previously described [112]. In short, the retroviral transfections were performed in series 
with drug selection to purify polyclonal-infected populations after each infection. First, am-
photropic retroviruses were produced by co-transfection of 293T cells with 8µg of the ampho-
tropic packaging plasmid pCL-10A1 and the specified pBabe retroviral expression construct 
using calcium phosphate precipitation. After 28h the viral supernatants were harvested and 
used to infect the HMECs applying 8µg/ml polybrene. The transfection efficiency was proven 
by parallel infections with GFP-expressing retroviruses. To prepare Bcl2L1 overexpressing 
HMLE cells, the 24
+
HMLE were transfected with the specific pBABEzeo construct as de-
scribed above. Infected cells were selected with 2µg/ml puromycin, 200µg/ml hygromycin, 
200µg/ml neomycin and 500µg/ml zeomycin. 
 
4.1.3.2 Isolation of floating MSP cells from HMLE cultures 
To generate MSP cells from their parental 24
+
HMLE, limited trypsination of 24
+
HMLE was 
performed. First, the respective 24
+
HMLE cells were cultured as described before (4.1.1). 
However, after applying Trypsin the cells were incubated for max. 3min at 37°C and 5% CO2. 
Afterwards, the cells were forced to detach by rapping on the cell culture flask. The cell sus-
pension containing only fast detached cells was transferred into a 15ml reaction tube and 
Trypsin was neutralized by adding TNS in the same amount. After centrifugation (8min, 
900rcf, RT), the supernatant was removed and the pellet was resolved in supplemented 
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MEGM medium and completely reseeded into a new cell culture flask. The process of limited 
trypsination was repeated at least three times every second day until the morphological 
change to mesenchymal cells was visible.  
4.1.4 Transient transfection with siRNA  
The selective knock down of target proteins was performed transiently by reverse transfection 
using siRNA (final concentration 12.5nM). For 6-well plates two different solutions were 
prepared. Solution A contained 0.5µl of siRNA (50µM) in supplemented MEGM medium 
(250µl), whereas solution B contained 15µl Lipofectamine 2000 in supplemented MEGM 
medium (250µl). After 5min incubation the solutions were combined in 6-well plates and in-
cubated for 20 to 45min at RT. Meanwhile, the cells were adjusted to the defined cell concen-
trations (1x10
5
cells/ml) depending on the experimental setup. The cell solution was added to 
the prepared transfection solution and mixed by swaying back and forth. The medium was 
changed after 24h incubation at 37°C and 5% CO2. Knock down was performed 24h up to 
48h before treatment, depending on the experimental setup.  
 
4.1.5 Chemical treatment 
Cells were seeded in the respective density 24h before chemical treatment. The medium was 
removed and fresh supplemented MEGM medium containing drugs in the indicated concen-
trations were added (Table 4.1). To treat the cells with chemotherapeutics in combination 
with inhibitors, the reagents were dissolved in DMSO and pre-diluted in supplemented 
MEGM medium, if necessary. Depending on the experimental outline the cells were treated 
with inhibitors in the presence or absence of chemotherapeutics for the respective time peri-
ods (Table 4.2). Control samples were treated with similar amounts of respective solvent. 
 






Carboplatin 27mM 0.75-1.5mM H2O 16h 
Cisplatin 3.45mM 5-40µM NaCl 8-16h 
Doxorubicin 4mM 200-500nM DMSO 24h 
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Table 4.2: Concentrations of inhibitors for cell treatment 




17AAG HSP90 170mM  5µM 
17DMAG HSP90 5mM  5µM 
Gossypol Bcl-xL 100mM 6-30µM 
LY294002 Akt 10mM 50µM 
Rapamycin mTOR 1mg/ml  50nM 
SB203580  p38 10mM  10µM 
SB431542 TGFβ 10mM  10µM 
SB600125 JNK 10mM  10µM 
U0126 Mek 25mM 25µM 
 
4.1.6 Proliferation Assay 
Cell proliferation was analyzed using the Celigo® Cytometer. A direct cell counting was per-
formed by defining the cell number per well on the basis of contrast in bright field light mi-
croscopy. For the measurement, the cells were seeded into 12-well plates (1.25x10
4
/ml) in 
duplicates or triplicates for every experimental setting. 24h after seeding the treatment was 
applied to the cells. Cell counting was performed once a day after adding fresh MEGM medi-
um for the respective time periods.  
 
4.1.7 Flow cytometry 
For analyzing caspase activation after chemotherapeutic treatment, the cells were analyzed by 
flow cytometry. To define healthy, early and late apoptotic cells, the Guava® Multi Caspase 
FAM Kit was used. This approach uses an inhibitor that binds specifically to the active site of 
caspases (so called “Caspase Reagent”). The inhibitor is conjugated to a fluorescent dye. The 
inhibitor is colligated to activated caspases with a fluoromethyl ketone group. The inhibitor is 
able to traverse the cell membrane. Once bound to an activated caspase, the inhibitor is 
trapped in the cell while unbound inhibitors diffuse out of the cell and are washed out during 
the washing step. The measured fluorescence signal is proportional to the number of active 
caspases that were represent in the cells at the beginning of the assay [113]. The implementa-
tion was done according the manufacturer’s instructions. In short, the supernatants of treated 
cells were harvested separately by centrifugation (8min, 900rcf, RT) while attached cells were 
harvested by trypsination (4.1.1). Afterwards, cells of the respective samples were combined 




 cells/ml in supplemented MEGM medium. 
The cells were mixed with the provided caspase working reagent and incubated for 1h at 37°C 
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and 5% CO2. After washing the cells with apoptosis buffer (3 times, 5min, 300g, RT), 7-
Aminoactinomycin (7-AAD) was added to the separate samples. 7-AAD intercalates into 
double-stranded DNA. 7-AAD is excluded by viable cells, however it can penetrate through 
membranes of dying and dead cells. It is therefore possible to simultaneously evaluate mem-
brane integrity and cell viability. The samples were measured with the Guava® EasyCyte™ 
flow cytometer by counting 5.000 events/sample.  
 
4.1.8 Immunohistochemistry  
To assess Bcl-xL level in human breast cancer, human tissues were analyzed for their Bcl-xL 
levels and mesenchymal character by immunohistochemistry and subsequent color intensity 
quantification in collaboration with Andreas Scheel, Institute for Pathology Nordhessen. Hu-
man tissue fixed in PBS-buffered formaline 4% was embedded in paraffin. 1.5µm sections 
were cut and treated with boric-acid/EDTA buffer for antigen-retrieval. Bcl-xL and Cy-
tokeratin 8 were stained using a specific primary antibody and UltraView DAB IHC detection 
kit on a BenchMark XT autostainer according to the manufacturer's instructions. For N-
Cadherin staining, a specific primary antibody together with the UltraView Universal Alka-
line Phosphatase Red Detection Kit was used.  
The slides were digitized with a ScanScope XT at 400x magnification and color intensity 
quantification was achieved with the ImageJ software [114] by manually selecting the areas 
of interest and performing a color deconvolution [115]. All experiments were in accordance 
with the local ethics committee. 
4.2 Molecular biology 
4.2.1 RNA standard techniques 
4.2.1.1 Isolation of total RNA 
Total RNA was isolated using Trizol and used for subsequent reverse transcription (4.2.1.3) 
and quantification by real time PCR (4.2.1.4). Cells in 6-well plates were washed with ice-
cold PBS followed by adding 1ml Trizol per sample. The samples were incubated for 5min at 
RT for cell lysis. Afterwards, 200µl chloroform per 1ml Trizol was added. The samples were 
shaken, incubated for 3min at RT and centrifuged to separate the different phases (15min, 
12.000g, 4°C). The RNA containing aqueous upper phase was transferred into another eppen-
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dorf tube and purified by precipitation with 500µl isopropanol per 1ml Trizol. The samples 
were shaken and centrifuged (10min, 12.000g, 4°C). Subsequently, the pellet was washed 
with 75% EtOH (5min, 7.500g, 4°C). To remove any protein contamination, the pellet was 
dissolved in 30µl nuclease free H2O and precipitated with 300mM NaAc and 70% EtOH 
(15min, 14.000rpm, 4°C). Afterwards, the RNA pellet was washed with 70% EtOH (5min, 
14.000rpm, 4°C) and air-dried. The RNA was dissolved in 30µl nuclease free H2O and heated 
for 5min at 55°C. The RNA was stored at -80°C.  
4.2.1.2 Quantification of RNA 
RNA concentration was measured with a NanoDrop spectrophotometer. To determine the 
concentration, the absorbance (A) at 260 nm was used while ratios of A260/A230 and of 
A260/A280 were used as indicators for the purity of the isolated RNA. Purified RNA should 
display values from 1.9 to 2.0 for of A260/A230 and 2.0 to 2.1 for of A260/A280. For distinct de-
viating values, the RNA was purified again (4.2.1.1). 
 
4.2.1.3 Reverse transcription 
For preparing cDNA, purified RNA (4.2.1.1) was reverse transcribed by using the reverse 
transcriptase M-MuLV. 1µg of the respective RNA was incubated with 4µl dNTP mix 
(2.5mM of each deoxyribonucleotide triphosphate, i.e. dATP, dCTP, dGTP and dTTP) and 
2µl primer which consisted of a combination of anchored oligo-dT primers (using 50µM 
dT23VN) and random nonamer primers (using 15µM nonamer primers). Additionally, nucle-
ase free water to a total volume of 16µl was added and the reagent mix was incubated for 
5min at 70°C in the PCR cycler. Afterwards, 4µl of a master mix was added to every sample. 
Every reaction mix was composed of the following reagents: 
 
2µl  reaction buffer    10x 
   0.25µl  RNase inhibitor    (10U) 
   0.125µl M-MuLV Reverse Transcriptase  (25U) 
   1.625µl RNase free water 
   4µl per sample 
 
Incubation:  Reverse transcription  42°C  60min 
   Inactivation of the enzyme 95°C  5min 
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To exclude contaminations with genomic DNA, a reaction without the reverse transcriptase 
was prepared for every RNA sample. Subsequently, the reactions were diluted with 30µl nu-
clease free water to a total volume of 50µl and stored at -20°C. 
4.2.1.4 Quantitative real time PCR 
To analyze gene expression patterns a quantitative real time PCR was performed based on 
Ishiguro et al. [116]. All samples were analyzed in triplicates and samples without reverse tran-
scriptase as well as a sample without cDNA were used as controls. Every reaction mix was 
composed of the following reagents: 
 
14µl   qRT-PCR reaction mix  25x 
   0.075µl primer forward   (100µM) 
   0.075µl primer reverse    (100µM) 
   9.85µl  RNase free water 
   1.0µl  cDNA 
   25µl per sample 
 
The qRT-PCR was done in 96-well plates and covered with a clear foil. The following pro-
gram was used: 
   Denaturation  95°C  2min 
 
   Denaturation  95°C  15s 
   Annealing  60°C  15s  40x 
   Elongation  72°C  30s 
 
The fluorescence dye SYBR-Green is able to intercalate into double-stranded DNA. The fluo-
rescence of each sample was measured after each cycle at the end of the elongation step. It is 
therefore possible to make a proposition about the amplification of the cDNA. Semi-
quantitative analysis of mRNA expression was conducted by measuring the Ct values of the 
reference gene 36B4 and the gene of interest. Ct values were defined by setting a threshold 
within the exponential slope of the amplified product. To determine the relative gene expres-
sion of the analyzed target genes, the ΔΔCt method was used:  
[117] 
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4.2.2 TaqMan® MicroRNA assay 
The TaqMan® MicroRNA assay was used to detect and quantify mature microRNAs (miR-
NA).  
 
4.2.2.1 Isolation of microRNA 
To isolate RNA for miRNA analysis, seeded cells were allowed to attach overnight, then 
washed with PBS and subsequently lysed by adding 1ml Trizol to every 6-well. After an in-
cubation of 10min at RT, 200µl Chloroform per 1ml Trizol was added and the samples were 
centrifuged (30min, 12.000rcf, 4°C). The RNA containing aqueous upper phase was trans-
ferred into a new reaction tube and purified by precipitation with three times of absolute 
EtOH of the recovered volume. The samples were incubated at -20°C overnight for precipita-
tion and afterwards centrifuged (30min, 10.000rcf, 4°C). The pellet was washed with 70% 
EtOH (5min, 12.000rcf, 4°C). To remove protein contaminations, the pellet was dissolved in 
100µl nuclease free H2O and precipitated with 2M NaAc and 80% EtOH for 30min at -20°C 
and subsequent centrifugation (30min, 14.000rpm, 4°C). Afterwards, the RNA pellet was 
washed with 80% EtOH (5min, 14.000rpm, 4°C) and air-dried. The RNA was dissolved in 
30µl nuclease free H2O and heated for 5min at 55°C. The RNA was stored at -80°C. 
 
4.2.2.2 MicroRNA specific reverse transcription 
For preparing miRNA specific cDNA, the isolated miRNA (4.2.2.1) was reversely transcribed 
using miRNA specific primer and the reverse transcriptase Multiscribe. miRNA concentration 
was measured as described before (4.2.1.2) and subsequently adjusted to 2ng/ml with nucle-
ase-free H2O. Every reaction mix was composed of the following reagents: 
 
0.15µl  dNTPs  
   1.5µl  RT buffer 
   0.188µl RNase inhibitor 
   4.162µl RNase free water 
   3µl  5x primer (for the corresponding miRNA) 
   9µl per sample 
 
1µl reverse transcriptase Multiscribe and 5µl RNA (2ng/ml) were added to every reaction 
mix. A reaction mix with water instead of the reverse transcriptase Multiscribe was used as 
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control. Subsequently, the reactions were diluted at least 1:15 with nuclease free H2O and 




Step time [min] temperature [°C] 
1 30 16 
2 30 42 
3 5 85 
 
4.2.2.3 TaqMan® PCR 
To quantify miRNA expression a TaqMan® PCR was performed according to the manufac-
turer´s instructions. All samples were analyzed in triplicates and samples without RT product 
(4.2.2.2) were used as controls. The following components were added per sample: 
 
10µl  TaqMan 2x universal PCR Master Mix  
  0.9µl  20x TaqMan Assay  
  7.77µl  RNase free water  
  1.33µl  RT product (4.2.2.2) 
  20µl per sample 
 
The TaqMan® PCR was done in 96-well plates and covered with a clear foil. For quantifica-
tion all samples were normalized to the nucleolar RNA U6. 
 
TaqMan®-PCR program: 
  AmpliTaq Gold enzyme activation   95°C  10min 
 
  Denaturation    95°C  15s 
  Annealing    60°C  60s 
 
To analyze the TaqMan® PCR, a threshold was set within the exponential slope of the ampli-
fied product to define Ct values. The relative amount of miRNAs was determined by using the 
ΔΔCt method:  
45x 
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[117] 
4.2.3 Gene expression analysis using microarray 
For comparison of total mRNA expression levels of 24
+
HMLE and MSP cells, a whole ge-
nome microarray was performed. For every cell line, three independent samples were pre-
pared. Total RNA was isolated using Trizol (4.2.1.1) and delivered to the transcriptome anal-
ysis laboratory (TAL) Göttingen. TAL controlled the RNA quality, measured the concentra-
tion and used 200ng of total RNA for reverse transcription into cDNA. Afterwards, the cDNA 
was transcribed into antisense RNA with a master mix containing the sample cDNA, dNTPs 
and T7 RNA polymerase. To label the sequence, Cy3-CTP was added to the transcription 
master mix as well. The labeled and purified antisense RNA was hybridized to the microarray 
slide, where the antisense RNA binds to complementary sequences printed on the array. The 
array slides were read out by laser application, measuring the fluorescence intensity of the 
Cy3 excitation. Strong emission at a particular RNA spot is correlated with a high expression 
of the specific gene in the sample. Subsequently, the data were analyzed by Lennart Opitz 
(TAL, Göttingen). For analyses, data of the three independent samples of each cell line were 
combined and the MSP data were analyzed relatively to the 24
+
HMLE data. The threshold of 
differentially regulated mRNA expression in MSP cells compared to 24
+
HMLE was set to 2 
and the induction was calculated as log2 values. Positive values indicate an up-regulation and 
negative ones a down-regulation of gene expression in MSP cells compared to 24
+
HMLE. 
4.3 Biochemistry and immunological methods 
4.3.1 Immuno-Slot-Blot assay  
To quantify the damaged DNA after Cisplatin treatment, the Cisplatin-adducts that were 
formed between the platinum atom and DNA after Cisplatin treatment were measured. DNA 
was firstly extracted with NucleoBond® AXG columns. Subsequently, DNA was analyzed 
for formed adducts by performing an Immuno-Slot-Blot assay based on Nehls et al. [118] in 
collaboration with Jürgen Thomale, University of Duisburg-Essen. 
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4.3.1.1 Extraction of DNA using NucleoBond® AXG columns 
For DNA extraction of Cisplatin treated cells NucleoBond® AXG columns were used accord-
ing to the manufacturer´s instructions. In short, the cells were harvested by trypsination 
(4.1.1) and adjusted to 1x10
7
/ml in PBS. The cells were disrupted by adding a specific lysis 
buffer and lysates were digested with Proteinase K for 1h at 50°C. The samples were applied 
to the NucleoBond® AXG columns and entered the resin by gravity flow. DNA was eluted 
twice with 5ml elution-buffer after three washing steps. Afterwards the DNA was precipitated 
with isopropanol (0.7 times) and incubated for 1h at RT. After centrifugation (30min, 
12.000rpm, 4°C) the pellets were washed with 70% EtOH and dried at 55°C. Finally, the pel-
lets were dissolved in 95µl nuclease free water and stored at -20°C.  
 
4.3.1.2 Immuno-Slot-Blot 
For analysis of the platinum atom-DNA intrastrand crosslinks, an Immuno-Slot-Blot was per-
formed by Jürgen Thomale, University of Duisburg-Essen. The extracted DNA from the Cis-
platin treated cells (4.3.1.1) was first denatured for 10min at 95°C. The samples were subse-
quently put on ice and diluted with 100µl ice-cold ammonium acetate (2M). For the Immuno-
Slot-Blot, a nitrocellulose Hybond membrane was soaked in 1M ammonium acetate, the slot-
blot apparatus was assembled and 200µl sample was applied onto the membrane. Afterwards, 
each slot was washed twice with 1M ammonium acetate. Subsequently, the membrane was 
removed from the apparatus. The membrane was soaked with 5xSSC for 5min and washed 
with H2O. Afterwards, the membrane was dried and the DNA was fixed by heating (2h, 
80°C). Unspecific antibody binding sites were blocked with blocking buffer for 2h. After-
wards, the membrane was incubated with the lesion specific antibody R-C18 (0.2µg/ml) in 
blocking buffer for 1h at RT [14]. Thereafter, the membrane was washed twice in PBS/0.2% 
Tween for 10min and then exposed to the anti-rat HRP-linked secondary antibody (1:2000 in 
blocking buffer) for 1h at RT. Afterwards the membrane was washed again and covered with 
1:1 mixed ECL solution for a few minutes. The luminescence was detected using an ECL-
reader. 
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4.3.2 Immunoblot analysis 
4.3.2.1 Generation of cell lysates for SDS-PAGE analysis 
Adherent cells were treated or transfected in 6-well plates for immunoblot analysis. To pre-
pare cell lysates for subsequent analysis by Sodium Dodecyl Sulfate PolyAcrylamide Gel 
Electrophoresis (SDS-PAGE), the supernatants of each well was collected in eppendorf tubes. 
Afterwards, the samples were centrifuged (5min; 3000rct; 4°C). The attached cells in the 6-
well plate were washed once with ice-cold PBS and covered with 85µl lysis buffer (contain-
ing protease inhibitors). The cells were scraped off and combined with the respective cell-
pellets of the supernatants. The protein concentration was measured with Nanodrop (4.3.2.2) 
and adjusted to the lowest protein concentration of the experiment by adding 6% Laemmli 
and lysis buffer (20µl total volume). For protein denaturation, the samples were boiled for 
3min at 95°C and finally sonicated for 10min. The samples were stored at -20°C.  
 
4.3.2.2 Determination of protein concentrations 
Protein concentration was measured using the BCA Protein Assay Kit based on the biuret re-
action according to the manufacturer´s instructions. In short, a master mix of 4% cupric sul-
fate and BCA solution (1:50) was added to the protein lysates (1:20) and incubated for 30min 
at 37°C. Afterwards the concentration was measured with Nanodrop and adjusted to the low-
est protein concentration in the experiment.  
 
4.3.2.3 Separation of proteins by SDS-PAGE 
To separate proteins under denaturing conditions, SDS-PAGE was performed as developed by 
Shapiro et al. in 1967 and Laemmli in 1970 [119; 120]. Separation of the proteins relies on 
their electrophoretic mobility. Prior the electrophoresis the proteins are boiled in presence of 
sodium dodecyl sulfate (SDS). Thus, SDS coats the proteins which results in a negative over-
all charge, so that proteins move to the anode if an electric field is applied. Thereby, proteins 
with lower weight travel faster through the pores of the gel, while large proteins are slower. 
The stacking gel contains large pores and the proteins are forming a stack between the leading 
chloride ions and the trailing ion Glycine. Afterwards proteins reach the resolving gel. Its pH 
is higher than that of the stacking gel and contains smaller pores. Thus, the proteins are sepa-
rated according to their molecular weight. Depending on the molecular weight of the investi-
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gated proteins, the different percentages of acrylamide/ bisacrylamide are used within the re-
solving gel. Details on the composition of the gels can be found in the following overview: 
 
Chemical Stacking gel Resolving gel  
Acrylamide/ bisacrylamide 5% 8-12% 
Tris, pH 6.8 (1M) 126mM - 
Tris, pH 8.8 (1.5M) - 375mM 
SDS (10%) 0.1% 0.1% 
APS (10%) 0.1% 0.1% 
TEMED 0.3% 0.4% 
 
First the resolving gel was casted between two glass plates, which were separated by two 
spacers. The gel was topped with isopropanol during the polymerization to prevent air contact 
and dehydration. The polymerized gel was rinsed with water and the stacking gel was filled 
on top. To form separated slots for the application of the protein lysates, a comb with 10 or 15 
teeth was fit in the liquid gel. 
For electrophoresis, the protein samples were boiled for 3min at 95°C and 18µl sample were 




The proteins that were separated by SDS-PAGE (4.3.2.3) were visualized using a tankblot 
technique based on Bittner et al. [121]. Thereby, proteins from the SDS gel are transferred to 
a nitrocellulose membrane whereon the proteins are detected with a primary antibody specific 
for the target protein and a secondary antibody that is coupled to horseradish peroxidase 
(HRP). Application of the substrate luminol that is oxidized by HRP then results in lumines-
cence. The emitted light is detected by a camera and thus protein bands are visualized. For the 
wet blot, the sponges, Whatman paper and nitrocellulose membrane with 0.2µm pore size 
were soaked with transfer buffer. Then the SDS gel was placed in a stack. Therefore, two 
sponges were assembled at the anode side, followed by three Whatman papers, the nitrocellu-
lose membrane and the SDS gel, followed by three Whatman papers and one sponge at the 
cathode side. The stack was placed into a blotting chamber, which was filled with transfer 
buffer and the blotting was performed at 100V for 120min at 4°C. Afterwards, the transfer 
chamber was disassembled and the nitrocellulose membrane was washed with water for a few 
seconds. Then, unspecific antibody binding sites of the membrane were blocked with block-
ing buffer for at least 30min at RT. Subsequently, the membrane was put into 5ml antibody 
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solution and incubated overnight at 4°C. After washing three times with TBS/T and three 
times with blocking buffer, the membrane was exposed to the respective secondary antibody 
(in 5ml blocking buffer) for at least 1h at RT. Afterwards the membrane was washed again as 




solution Luminol and stable per-
oxide solution were
 
mixed 1:1 and applied onto the membrane. The luminescence was detect-
ed using a Chemocam HR 16 3200 imager. Weak signals were detected with the more sensi-
tive substrate solution SuperSignal West Femto Maximum.  
4.4 MSP RAS injection in mice and HSP90 inhibition 
Xenograft experiments were performed to assess the inhibition of HSP90 in MSP RAS cells 
derived tumors in mice. Six-week-old nude mice were anesthetized with 3-4% Isofluran, fol-
lowed by γ-irradiation (1.87Gy/min). MSP RAS cells have been grown to 70% confluence 
and were trypsinized as described previously (4.1.1). Subsequently, cells were resuspended in 
antibiotic free MEGM medium at 1x106 cells per 100µl. Cell suspension was diluted 1:1 with 
Matrigel™ immediately before injection in the flank region of the nude mice. Tumor growth 
was monitored daily using a caliper. In the phase of exponential tumor growth, approximately 
three weeks after injection and tumor volume of 200mm³, xenograft mice were randomly as-
signed to two groups. 17DMAG was dissolved in sterile H2O and stored at -20°C until use. 
For daily intraperitoneal administration of 0.06mg/10µl 17DMAG (200µl/mice), 17DMAG 
was diluted 1:1 with 10% glucose solution.  
4.5 Statistical analysis 
Statistical significances were defined by the unpaired, two-tailed student’s t-test using Mi-
crosoft Excel. Results were considered as significant for p-values below 0.05. In figures, as-
terisks indicate resulting p-values as follows: * p < 0.05, ** p < 0.01, *** p < 0.001. n.s. = not 
significant. n in figure legends indicates the number of independent experiments 
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5. Results 
5.1 EMT results in chemotherapeutic resistance 
5.1.1 HMLE (RAS) system as a convenient model for EMT 
It is well established that Epithelial Mesenchymal Transition (EMT) is not only involved in 
embryogenic development but rather plays an important role in tumor metastasis as well as in 
chemotherapeutic resistance. In different tumor types typical markers for EMT occur and 
were found to be accompanied by resistances to different chemotherapeutic drugs [105]. To 
investigate whether EMT results in chemotherapeutic resistance, a convenient model system 
was an absolute need. We therefore were kindly provided with the HMLE and HMLE RAS 





HMLE RAS cells display the parental cell population in their original epithelial cell shape 
and behavior, while MSP and MSP RAS cells are a mesenchymal subpopulation originating 
from the 24+HMLE or 24+HMLE RAS, respectively, and display properties of cells upon 
EMT [110; 111; 112].  
To validate the respective markers for EMT in HMLE and HMLE RAS we made use of qRT-
PCR and micro array analysis. mRNA of untreated cells was isolated and gene expression of 
morphological markers like Vimentin and E-Cadherin as well as the cell surface marker 
CD24 and genes that are directly affected by EMT-induced signalling pathways were identi-
fied. As expected, the mesenchymal marker Vimentin is up-regulated in MSP (RAS) cells, 
while the epithelial marker E-Cadherin is decreased. Concomitant with EMT, Zeb1, Zeb2 and 
Twist gene expression were found to be increased in MSP and MSP RAS together with the 
Wnt-target genes Axin2, MMP7 and cMyc, which are distinctively up-regulated by activated 
Wnt signaling pathway (Figure 5.1A, C). Additionally, micro array analysis resulted in 812 
differentially regulated genes implicating the substantial alteration of morphological and cel-
lular processes associated with EMT (Figure 5.1B, appendix). 
In conclusion, the HMLE as well as HMLE RAS system display characteristic markers for 
cells before and upon EMT. Not only the morphological change from epithelial to mesen-
chymal phenotype, but also cellular signalling pathways that are affected by EMT seemed to 
be active in MSP and MSP RAS. This is reflected by the up-regulation of Wnt-responsive 
genes (Axin2, MMP7, cMyc) and TGFβ/Smad regulated genes (Zeb1, Zeb2). These results 
suggest the HMLE and HMLE RAS systems as an acceptable model for EMT. 




Figure 5.1: Validation of differentially regulated EMT markers in cells before and upon EMT.  
(A, C) HMLE (A) and HMLE RAS cells (C) were harvested 24h after seeding. mRNA was isolated and mRNA 
level of the indicated genes were analyzed by qRT-PCR. mRNA level were normalized to 36B4. Data show 
mean ±SD of n=3. (B) Micro array analysis was performed in untreated 24
+
HMLE and MSP cells to contrast 
EMT regulated genes. The heat map represents the top 50 deregulated genes in MSP cells relative to the 
24
+
HMLE cells. By setting a threshold of differentially regulated mRNA expression in 24
+
HMLE compared to 
MSP cells to 2-fold, 812 genes were found to be differentially regulated upon EMT.  
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5.1.2 In response to Cisplatin no apoptosis is detectable in MSP and MSP RAS cells 
To address the question, whether EMT affects the response to chemotherapy HMLE and 
HMLE RAS cells were exposed to Cisplatin for 8h or 16h. Thereupon, cells were harvested 
and apoptotic markers were identified by western blot. Activation of Caspase 3 (cleaved 
Caspase 3) and cleavage of PARP imply apoptosis induction after chemotherapeutic treat-
ment. These apoptotic mediators were detectable for 24
+
HMLE as well as for 24
+
 RAS cells, 
but not for MSP or MSP RAS cells (Figure 5.2B, C). Even higher concentrations of Cisplatin 
(60µM) did not result in generic detached rounded cells in case of MSP cells (Figure 5.2A). 
As an alternative measure to define apoptotic cells, activated caspases were determined by 
flow cytometry. MSP RAS cells treated with 30µM Cisplatin displayed less amounts of apop-
totic cells compared to 24
+
 RAS cells (Figure 5.2D), indicating lack of activation of apoptotic 




Figure 5.2: In response to Cisplatin no induction of apoptosis is detectable in MSP RAS cells.  
(A) 16h after seeding HMLE cells were treated with 40µM or 60µM Cisplatin for 8h. Thereafter, morphology of 
cells was checked with phase-contrast microscopy. (B, C) HMLE (B) and HMLE RAS cells (C) were treated 
with 20µM or 40µM Cisplatin for 16h. Cells were harvested and lysates were analyzed by western blot. Actin 
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staining was used as loading control and arrows are indicating the intended staining. One representative experi-
ment of n=3 is shown. (D) 16h after seeding HMLE RAS cells were treated with 30µM Cisplatin for 16h. Cells 
and supernatants were harvested and apoptotic cells were determined using the Guava® Multi Caspase FAM Kit 
and flow cytometry. Data show mean ±SD of n=3. 
 
It was recently published that EMT activators are able to directly manipulate the cell-cycle 
progression impairing proliferative activity [122; 123]. Diminished cell proliferation is as-
sumed to protect from DNA damage and would result in delayed or missing induction of 
apoptosis upon chemotherapeutic treatment [124]. We therefore performed cell proliferation 
assays in HMLE as well as HMLE RAS cells. Proliferation was measured over 2d by direct 
cell counting, defining the cell number per well using a Celigo® cytometer. The analysis 
showed that 24
+
HMLE cells displayed different growth rates compared to MSP cells, while 
they were comparable for HMLE RAS cells (Figure 5.3A, B mock). Implicating that different 
growth rates are not the reason for lacking apoptosis, we decided to use the HMLE RAS cell 
system for further analysis. To this end, HMLE RAS cells were treated with 5µM or 10µM 
Cisplatin for 24h and subsequently, Cisplatin was replaced by fresh medium and the cell pro-
liferation were measured over 7d every 24h by direct cell counting. Strikingly, MSP RAS 
cells continued their proliferation 5d after Cisplatin withdrawal, while 24
+
 RAS cells did not 
recover (Figure 5.3B). Considering these results, we were interested to know whether Cispla-
tin is absorbed by MSP RAS and explored the Cisplatin adducts that were formed between the 
platinum atom and DNA after Cisplatin treatment. We made use of an Immuno-Slot-Blot as-
say in cooperation with J. Thomale, University of Duisburg-Essen, applying an antibody that 
specifically recognizes the platinum atom bound to GpG [14]. These data demonstrated that 
24
+
 RAS and MSP RAS display equal amounts of Cisplatin adducts after treatment (Figure 
5.4). This experiment argues that DNA of 24
+
 RAS cells and MSP RAS cells is damaged to 
the same degree by chemotherapy. Thus, neither different cell proliferation nor Cisplatin 













Figure 5.3: MSP RAS cells recover from Cisplatin treatment.  
(A) 8h after seeding HMLE cells, direct cell counting was performed for 48h by defining the cell number per 
well using a Celigo® cytometer. One representative experiment of n=3 is shown. (B) 24h after seeding HMLE 
RAS were treated with 5µM or 10µM Cisplatin for 24h. Afterwards, cells were washed with supplemented 
MEGM medium and kept in culture. Cell number was measured once a day for 7d with a Celigo® cytometer af-
ter adding fresh medium. Non-treated cells were used as control. Data show mean ±SD. One representative ex-
periment of n=3 is shown. 
 
 
Figure 5.4: Cells before and upon EMT display equal amounts of Cisplatin adducts.  
24h after seeding HMLE RAS cells were treated with 20µM or 40µM Cisplatin for 16h. Afterwards, DNA was 
extracted with NucleoBond® AXG columns and analyzed for formed adducts by Immuno-Slot-Blot assay. Ex-
periments were conducted with J. Thomale, University of Duisburg-Essen. Non-treated cells were used as con-
trol. Data show mean ±SD of n=3. 
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5.1.3 MSP RAS cells display a general apoptosis deficit 
Given the above results, we made use of different inhibitors manipulating distinct pathways 
that are involved in EMT or cell survival to test whether this would sensitize MSP RAS cells 
to Cisplatin treatment: First, we inhibited the Akt-signalling pathway by Akt and mTor inhibi-
tors. Akt is a pro-survival protein, which is described as mediator of chemoresistance to Cis-
platin [125]. Furthermore, we manipulated the mitogen activated protein kinase Mek and in-
hibited JNK and p38, which are involved in the activated Wnt-signalling pathway [126]. MSP 
RAS cells were treated with the respective inhibitors in presence or absence of Cisplatin; sub-
sequently, cells were harvested and analyzed for induced apoptosis mediators by western blot. 
None of the treatments resulted in PARP cleavage; implicating no effects on the response to 
Cisplatin in MSP RAS cells (Figure 5.5A, C, D). Even by inhibiting TGFβ-induced pathways 
no changes concerning cleaved PARP were detectable for MSP RAS cells (Figure 5.5B). On 
that account, it was tested whether other chemotherapeutics were able to induce apoptosis in 
MSP RAS cells. To this end, HMLE RAS cells were exposed to Carboplatin, Doxorubicin or 
Neocarzinostatin (NCS) followed by western blot analyses for PARP cleavage. Strikingly, 
none of the chemotherapeutics induced apoptosis in MSP RAS cells while 24
+
 RAS cells 
showed PARP cleavage for every treatment (Figure 5.6). These findings raised the question 
whether it is possible to induce apoptosis in MSP RAS cells independent from DNA damage. 
To test this, HMLE RAS cells were exposed to several concentrations of the death ligands 
Trail or TNFα. Since these ligands induce the transcription of NFκB and thus pro-survival 
pathways as a negative feedback, all treatments were performed in the presence of Cyclo-
heximide a protein synthesis inhibitor preventing NFκB translation [127]. For 24
+
 RAS cells 
activation of Caspase 3 as well as PARP cleavage was detectable for both treatments. But 
even for higher concentrations of Trail no PARP cleavage was identified for MSP RAS cells 
(Figure 5.7A). Only for TNFα concentrations four times higher compared to the concentra-
tions used for 24
+
 RAS cells, activation of the apoptosis mediators was observed (Figure 
5.7B).  
In summary, these results suggest that EMT results in MSP RAS cells that are resistant to the 
induction of apoptosis through chemotherapy or independent from DNA damage through 
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Figure 5.5: Manipulation of distinct signalling pathways does not sensitize MSP RAS cells towards Cispla-
tin.  
(A-D) 24h after seeding HMLE RAS cells (A) or MSP RAS cells alone (B-D) were treated with the indicated 
inhibitors of different signalling pathways in the presence or absence of 20µM or 40µM Cisplatin for 16h. Af-
terwards, cells were harvested and lysates were analyzed by western blot. Actin staining was used as loading 
control. Controls were treated with similar amounts of DMSO, n=1.  
 
Figure 5.6: MSP RAS are resistant to a variety of chemotherapeutics.  
(A-C) 16h after seeding HMLE RAS cells were treated with the indicated concentrations of Carboplatin for 16h 
(A), Doxorubicin for 24h (B) or NCS for 20h (C). Thereafter, cells were harvested and lysates were analyzed by 
western blot. Actin staining was used as loading control. Controls were treated with similar amounts of the re-
spective solvent, n=1. 




Figure 5.7: In response to the treatment with death ligands no apoptosis is detectable in MSP RAS cells.  
(A, B) 16h after seeding HMLE RAS cells were treated with the indicated concentrations of Trail (A) or TNFα 
(B) in presence of 20µg/ml CHX for 6h. Subsequently, cells were harvested and lysates were analyzed by west-
ern blot. Controls were treated with Ethanol for CHX or sterile H2O for Trail and TNFα. Actin staining was used 
as loading control and arrows are indicating the intended staining. Shown is one representative experiment of 
n=3. 
5.2 Bcl-xL overexpression protects MSP RAS cells from chemotherapy 
5.2.1 EMT causes overexpression of the anti-apoptotic protein Bcl-xL 
Previous results indicated that the failure of induction of apoptosis in MSP RAS cells is inde-
pendent of chemotherapeutic treatment or exposure to death ligands. We hypothesized that 
mediators related to apoptosis are changed in cells upon EMT. We therefore checked our mi-
cro array data for differentially regulated genes that are associated with apoptosis. In fact, 
gene expression of the apoptotic gene Bcl2L1 was found to be two fold up-regulated in MSP 
cells compared to 24
+
HMLE cells (appendix). The Bcl2L1 gene encodes two different pro-
teins: the pro-apoptotic variant Bcl-xS and the anti-apoptotic variant Bcl-xL [128]. Quantita-
tive RT-PCR for HMLE and HMLE RAS cells showed a two to three fold induction of 





cells, respectively. We further checked the protein levels for Bcl2L1 by western blot and 





RAS cells, respectively (Figure 5.8A, B). To assess whether the anti- or 
pro-apoptotic variant of Bcl2L1 is up-regulated in MSP and MSP RAS cells, we used an anti-
body that recognizes an epitope that is solely present in Bcl-xL, but missing in Bcl-xS. We 
obtained the same result for the specific (sc-8392) compared to the unspecific Bcl-xL anti-
body (cs-2764), i.e. only one signal at the height of Bcl-xL (26kDa) and no signal correspond-
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ing to Bcl-xS (19kDa) (Figure 5.8C). Apart from Bcl-xL, we were not able to detect other up-




Figure 5.8: EMT results in overexpression of the anti-apoptotic protein Bcl-xL.  
(A, B) HMLE (A) and HMLE RAS cells (B) were harvested 24h after seeding, mRNA was isolated and mRNA 
level of Bcl2L1 variants were analyzed using qRT-PCR. mRNA level were normalized to 36B4. Data show 
mean ±SD of n=3. Protein lysates were analyzed for Bcl2L1 by western blotting. (C, D) HMLE RAS were har-
vested 24h after seeding and lysates were analyzed for anti-apoptotic proteins by western blotting. Actin staining 
was used as loading control and arrows are indicating the intended staining. For Bcl2L1 and Bcl-xL: * indi-
cates deamidated protein, # indicates unmodified protein. For western blot one representative experiment of 
n=3 is shown. 
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5.2.2 Bcl-xL siRNA knock down sensitizes MSP RAS cells to apoptosis induction 
To investigate the role of Bcl-xL in chemotherapeutic resistance, we performed Bcl-xL medi-
ated siRNA knock down, treated the cells with Cisplatin and subsequently, analyzed cell ly-
sates for apoptosis induction by western blot. siRNA targeting Bcl-xL efficiently depleted 
cells of the protein (Figure 5.9A). Compared to mock and scr control-treated cells, Bcl-xL-
depleted MSP RAS cells displayed strong activation of Caspase 3 as well as PARP cleavage 
in the presence of Cisplatin (Figure 5.9A). Analyzing the activated caspases with flow cytom-
etry for Bcl-xL-depleted MSP RAS cells a significant increase in the amount of apoptotic 
cells was visible (Figure 5.9B). This confirmed the results obtained with western blot. Fur-
thermore, we found that the Bcl-xL-mediated siRNA knock down caused apoptosis in MSP 
RAS cells after exposure to Trail, independent from DNA damage (Figure 5.9C). Thereupon, 
it was tested whether overexpression of Bcl-xL would rescue the 24
+
HMLE from induction of 
apoptosis after Cisplatin or Trail treatment. For this purpose, Weinberg and colleagues pro-
vided us with 24
+
HMLE cells that stably overexpress Bcl2L1 (24
+Bcl-xL
) and applied Cisplatin 
and Trail to these cells. Indeed, 24
+Bcl-xL 
displayed neither activated Caspase 3 nor cleaved 
PARP (Figure 5.10A, B). These results support the notion of Bcl-xL as a key mediator in pre-
venting apoptosis in cells upon EMT and implicates that the failure of apoptosis induction in 




Figure 5.9: Bcl-xL siRNA knock down sensitizes MSP RAS cells to Cisplatin and Trail treatment.  
Legend on the next page. 
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Figure 5.9: Bcl-xL siRNA knock down sensitizes MSP RAS cells to Cisplatin and Trail treatment. (A) 32h 
after siRNA mediated knock down of Bcl-xL, MSP RAS cells were treated with 20µM or 40µM Cisplatin for 
16h. Subsequently, cells were harvested and lysates were analyzed by western blot. (B) 32h after siRNA mediat-
ed knock down of Bcl-xL, MSP RAS were treated with 30µM Cisplatin for 16h. Cells and supernatants were 
harvested and apoptotic cells were determined using the Guava® Multi Caspase FAM Kit and flow cytometry. 
Data show mean ±SD of n=3. Student´s t-test was performed for statistical analyses. (C) 48h post transfection 
MSP RAS cells were treated with 100ng/ml Trail in the presence of 20µg/ml CHX for 6h. Thereafter, cells were 
harvested and lysates were analyzed by western blot. Untreated and scr siRNA-transfected cells were used as 
control, while Actin staining was used as loading control. Arrows are indicating the intended staining. A, C: One 
representative experiment of n=3 is shown.  
 
Figure 5.10: Bcl-xL overexpression in 24+HMLE cells results in resistant cells.  
(A, B) 24
+Bcl-xL
 and HMLE RAS cells were treated with 40µM Cisplatin for 16h (A) or 100ng/ml Trail in the 
presence of 20µg/ml CHX for 6h (B). Subsequently, cells were harvested and lysates were analyzed by western 
blot. Untreated cells were used as control, while Actin staining was used as loading control. n=1. 
5.2.3 Bcl-xL protein level are increased in disseminated tumor cells in human tissue 
Additionally, we were interested to see whether we can transfer our results to clinical breast 
cancer tissues. We therefore collaborated with A. Scheel, Institute for Pathology Nordhessen, 
and assessed Bcl-xL protein level in human ductal carcinoma (DIC). We made use of im-
munohistochemistry on formalin-fixed paraffin-embedded tumor material. 26 cases of DIC 
including all molecular subtypes of human breast cancer as luminal A, B and triple negative, 
were validated for Bcl-xL level. The data showed that Bcl-xL was detected in every specimen 
but differences in protein levels did not correlate with subtypes or the parameters of hormone 
receptors, Her2 status, stage, age and sex. Bcl-xL protein expression was heterogeneously dis-
tributed within the respective specimen, whereby six cases display pronounced protein levels 
in tumor cells at the tumor-stroma-interface and in disseminated tumor cells (Figure 5.11A). 
As an alternative measure, digital color intensity quantification corroborated the increased 
Bcl-xL staining (Figure 5.11B). The disseminated high positive Bcl-xL cells expressed the ep-
ithelial marker Cytokeratin 8, indicating that morphologically these cells seem to originate 
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from the solid tumor formations (Figure 5.11C). However, the observed heterogeneous ex-
pression of N-Cadherin that partly overlapped with Bcl-xL expression implies that these are 




Figure 5.11: Bcl-xL protein levels are increased at the tumor-stroma-interface and in disseminated tumor 
cells.  
Continued on the next page. 
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Figure 5.11: Bcl-xL protein levels are increased at the tumor-stroma-interface and in disseminated tumor 
cells. (A-D) Human tissue fixed in PBS-buffered 4% formalin was embedded in paraffin. 1.5µm sections were 
cut and treated with boric-acid/EDTA buffer for antigen-retrieval (A) IHC for Bcl-xL. 3 images of 4 clinical cas-
es, magnification 200x. Column 1: Representative cells highlighted (black arrows), columns 2-4: Magnifications 
of areas indicated in the first column. (B) Quantification of DAB precipitate color-intensity in the two highlight-
ed regions (borders green, red); boxplots of respective intensities. '1'-'4': Magnified details as indicated. (C) Cy-
tokeratin 8 IHC. (D) N-Cadherin IHC (Fast Red). B-D: 400x magnification, corresponding regions. Experiments 
were conducted with A. Scheel, Institute for Pathology Nordhessen.  
5.2.4 Bcl-xL level in MSP RAS cells are not detectably regulated by translation, tran-
scription factors, miRNA or proteasomal degradation 
Since we have shown that EMT obviously causes the overexpression of the anti-apoptotic 
protein Bcl-xL in MSP and MSP RAS cells, we were interested to examine how this induction 
is regulated. To assess, whether translational or proteasomal processes are involved we made 
use of time chase experiments and exposed the HMLE RAS cells to Cycloheximide or 
MG132 up to 4h and analyzed protein lysates for Bcl-xL afterwards. Cycloheximide inhibits 
the elongation of translation by binding the ribosome and inhibiting eEF2-mediated transloca-
tion of the mRNA [129]. Regulation on this level would result in decreased protein levels as it 
is visible for the control staining Hif1α. Bcl-xL protein levels were neither affected by Cyclo-
heximide in 24+ RAS cells nor in MSP RAS cells (Figure 5.12A). In contrast to Cyclo-
heximide, the proteasomal inhibition by MG132 would result in protein accumulation. This 
was the case for the control staining Hif1α, but no increase were observed for the levels of 
Bcl-xL in HMLE RAS (Figure 5.12B), suggesting that Bcl-xL is not a high-turnover protein.  
 
It was recently published that miRNAs (miR) are directly associated with EMT in develop-
ment and cancer. Peter reviewed that especially let7 miRNA / miR-98 and the miR-200 fami-
ly are linked to cell differentiation and EMT [130]. Additionally, Shimizu et al. showed that 
low let7 miRNA expression results in increased Bcl-xL protein levels [79]. To investigate the 
role of miRNA concerning the overexpression of Bcl-xL in MSP RAS cells we used Taq-
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man® PCR as an alternative measure to define the expression levels of miRNA let7a, b and 
let7f in HMLE RAS cells. However, quantification of miRNA let7 revealed that the expres-
sion levels do not differ in HMLE RAS cells (Figure 5.13A). Apart from miRNA let7, the 
miR-200 family is involved in processes that regulate EMT. In this context, miR-200 expres-
sion contributes to an epithelial phenotype by preventing the expression of the transcriptional 
repressors Zeb1 and Zeb2, which are highly induced upon EMT [131]. To explore, whether 
miRNAs are involved in Bcl-xL translation in general, we decided to perform a siRNA-
mediated knock down of Dicer, a protein that is necessary for the maturation of miRNA from 
pre-miRNA. Depletion of Dicer abrogates the processing of pre-miRNA and therefore de-
pletes the cell of mature miRNAs. If Bcl-xL mRNA is degraded by miRNA, it would be ex-
pected that upon Dicer siRNA knock down Bcl-xL level are increased in 24
+ 
RAS cells. The 
knock down efficiency was monitored by qRT-PCR, but we did not detect any changes in 
Bcl-xL level for 24
+ 
RAS cells or MSP RAS cells (Figure 5.13B, C). 
 
 
Figure 5.12: Bcl-xL overexpression is not detectably regulated by translation or proteasomal degradation. 
Legend on the next page. 
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Figure 5.12: Bcl-xL overexpression is not detectably regulated by translation or proteasomal degradation. 
(A, B) 16h after seeding HMLE RAS cells were exposed to 20µg/ml CHX (A) or 20µM MG132 (B) up to 4h. 
Thereafter, cells were harvested and lysates were analyzed for Bcl-xL by western blot. Actin staining was used 
as loading control, while Hif1α staining was used as positive control for treatment. Ethanol or DMSO was used 
as control for CHX (A) or MG132 (B) treatment, respectively. Arrows are indicating the intended staining.  n=1. 
 
Figure 5.13: Bcl-xL overexpression is not detectably regulated by miRNAs.  
(A) HMLE RAS cells were harvested 24h after seeding. Total mRNA was isolated and miRNA levels of miRNA 
let7 variants were analyzed using Taqman® PCR. miRNA levels were normalized to U6. Data show mean  ±SD 
of n=3. (B) 48h after siRNA-mediated Dicer knock down HMLE RAS cells were harvested. mRNA was isolated 
and mRNA levels of Dicer were analyzed using qRT-PCR. mRNA levels were normalized to 36B4. Non-
transfected cells or scr siRNA were used as control. n=1 (C) 48h after siRNA-mediated Dicer knock down 
HMLE RAS cells were harvested and lysates were analyzed for Bcl-xL by western blot. Actin staining was used 
loading control. n=1. 
Scheel et al. have shown that the Wnt-signalling pathway is activated in MSP cells [110]. Ac-
tive Wnt pathway results in phosphorylated JNK and subsequently in activated cJun. The 
transcriptional activator cJun is a pivotal component of the AP-1 transcription factor complex 
and able to induce autonomous gene expression [132]. In general, the dimeric transcription 
factor AP-1 consists of proteins that belong to the Jun (e.g. cJun and JunD), Fos (e.g. cFos), 
Maf and ATF family and bind to the AP-1 binding site [74]. The promoter region of Bcl-xL 
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contains various transcription factor binding sites including two sites for AP-1 [133]. We 
therefore addressed the question, whether manipulation of AP-1 would alter Bcl-xL level in 
MSP RAS cells. Initially, we were able to validate the cJun overexpression in MSP RAS cells 
(Figure 5.14A) and thereupon tested the effects of the siRNA-mediated cJun knock down in 
MSP RAS cells. Despite an efficient cJun siRNA knock down, no changes for Bcl-xL mRNA 
or protein levels were observed (Figure 5.14B, C). Given the fact that AP-1 can consist of ei-
ther Jun family protein homodimers or Jun-Fos heterodimers, we were interested to investi-
gate the Bcl-xL level after siRNA-mediated knock down of combinations of cJun, cFos or 
JunD [134]. The knock down efficiency of cFos and JunD was defined by qRT-PCR (Figure 
5.15C, D). However, when Bcl-xL protein levels were analyzed by western blot 48h after 
knock down, no differences were visible in the knock down samples compared to the mock 
and scr control (Figure 5.15A). Because of the high stability of chromatin-associated tran-
scription factors, we decided to perform a reiterated siRNA-mediated AP-1 knock down 48h 
after the first knock down. After 96h cells were harvested and the protein lysates were ana-
lysed for Bcl-xL. The knock down efficiency was monitored by Cyclin D1 and cJun, but no 
differences were detectable. It can be concluded, that the reiterated knock down was not suc-
cessful. Accordingly, no changes for Bcl-xL protein levels were detectable. Since the combi-
nation of different siRNA in one experiment can cause reduced knock down efficiencies, this 
could be the reason for the lacking siRNA efficiencies in this experiment.  
 
 
Figure 5.14: EMT results in overexpression of the transcription factor cJun, but this is not the reason for 
Bcl-xL accumulation. 
(A) HMLE RAS cells were harvested 24h after seeding. Protein lysates were analyzed for cJun by western blot-
ting. (B) 48h after siRNA-mediated cJun knock down MSP RAS cells were harvested and lysates were analyzed 
for Bcl-xL level by western blot. Actin staining was used as loading control. One representative experiment of 
n=3 is shown. (C) 48h after siRNA mediated cJun knock down MSP RAS were harvested. mRNA was isolated 
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and mRNA levels of cJun and Bcl-xL were analyzed using qRT-PCR. mRNA levels were normalized to 36B4. 
Non-transfected cells and scr siRNA were used as control. Data show mean ±SD of n=3. 
 
 
Figure 5.15: AP-1 transcription factor knock down has no detectable effect on Bcl-xL level in MSP RAS 
cells.  
(A) 32h after siRNA-mediated knock down of AP-1 with combinations of cFos, cJun and JunD siRNA, MSP 
RAS cells were treated with 20µM Cisplatin for 16h. Subsequently, cells were harvested and lysates were ana-
lyzed by western blotting. Untreated cells were used as control. For Bcl-xL: * indicates deamidated protein, 
# indicates unmodified protein. (B) 96h after reiterated siRNA-mediated knock down of AP-1 with combina-
tions of cFos, cJun and JunD siRNA, cells were harvested and lysates were analyzed for Bcl-xL level by western 
blot. Actin staining was used as loading control, while CyclinD1 staining was used as positive control for treat-
ment. (C-D) 48h after siRNA-mediated knock down of cFos (C) or JunD (D) cells were harvested, mRNA was 
isolated and mRNA levels of cFos (C) or JunD (D) and Bcl-xL were determined using qRT-PCR. mRNA levels 
were normalized to 36B4. Non-transfected cells and scr siRNA were used as control. n=1. 
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Besides an AP-1 binding site, the Bcl-xL gene contains transcription factor binding sites that 
are bound by STAT transcription factors, especially by STAT5 [133]. We therefore tested, 
whether STAT-mediated siRNA knock down effected Bcl-xL level. qRT-PCR analysis 
showed efficient knock down of STAT3 as well as STAT5a and STAT5b on mRNA level 
(Figure 5.16B, C). 32h after STAT siRNA knock down; MSP RAS cells were treated with 
20µM Cisplatin and the induction of apoptosis as well as Bcl-xL protein level were defined 
by western blot analyses. The knock down efficiency of STAT siRNA 48h after transfection 
was indirectly monitored by decreased Cyclin D1 protein level. In contrast, no changes were 
evident for Bcl-xL or apoptosis-induction in dependence on STAT knock down. These find-
ings for STAT are in line with the result for the siRNA-mediated knock down of AP-1. It can 
be concluded that these transcription factors do not regulate the Bcl-xL level in MSP RAS 
cells to a detectable degree. 
 
 
Figure 5.16: STAT siRNA knock down has no detectable effect on Bcl-xL level in MSP RAS cells.  
(A) 32h after siRNA mediated knock down of STAT3, STAT5a and STAT5b, MSP RAS cells were treated with 
20µM Cisplatin for 16h. Subsequently, cells were harvested and lysates were analyzed for Bcl-xL level by west-
ern blot. Actin staining was used as loading control while CyclinD1 staining was used as positive control for 
treatment. Untreated cells were used as control. (C-D) 48h after siRNA-mediated transfection of STAT3 (C) or 
STAT5a and STAT5b (D) cells were harvested, mRNA was isolated and mRNA levels of STAT3 (C) or 
STAT5a and STAT5b (D) were analyzed using qRT-PCR. mRNA levels were normalized to 36B4. Non-
transfected cells and scr siRNA were used as control. n=1. 
5 Results  70 
5.3 Overcoming the chemoresistance of MSP RAS cells by the inhibition and destabili-
zation of Bcl-xL 
5.3.1 Gossypol stops MSP RAS cell proliferation and induces autophagy 
Cells that have undergone EMT pose a challenge to cancer therapy as they develop chemo-
therapeutic resistance which results in metastasis and relapse of cancer disease. We therefore 
aimed to overcome the chemotherapeutic resistance of MSP RAS cells overexpressing Bcl-
xL. To this end, we decided to use the Bcl-xL inhibitor Gossypol which mimics the Bcl-2 
homology domain 3 (BH3), binds to Bcl-2 proteins and neutralizes them [135]. To investigate 
the effect of Gossypol on HMLE RAS cells we performed cell proliferation assays. HMLE 
RAS cells were treated with 6 to 30µM Gossypol for 24h. Subsequently, Gossypol was re-
placed by fresh medium and the cell proliferation was measured over 8d every 24h by direct 
cell counting, defining the cell number per well using a Celigo® cytometer. While Gossypol 
concentrations up to 18µM displayed no distinctive effect on HMLE RAS cell proliferation 
(Figure 5.17B), 24µM and 30µM Gossypol disrupted the cell proliferation of 24
+ 
RAS cells as 
well as MSP RAS cells with no regain of cell viability (Figure 5.17C). 
 
When we applied Gossypol in parallel with Cisplatin for 16h to HMLE RAS it was obvious 
that apoptosis was still not induced in MSP RAS cells. Since Gao et al. showed that Gossypol 
is able to induce autophagy in cancer cells, we analyzed cell lysates for apoptosis and autoph-
agy by western blot [135]. Thus, we examined the autophagy marker LC3a/b I. LC3a/b I is a 
widely used marker for autophagy because of its lipidation and recruitment to the autophago-
somes after induction of autophagy in the cell. The lipidation of LC3a/b I results in LC3a/b II 
which displays an increase in the electrophoretic mobility of this protein on gels compared to 
LC3a/b I [136]. The signal for LC3a/b II is therefore below the staining for LC3a/b I in west-
ern blot. Thus, induced autophagy is visible by increased levels of LC3a/b II. Indeed, for MSP 
RAS cells no activation of Caspase 3 was detectable. However, the signal for LC3a/b II ac-
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Figure 5.17: The Bcl-xL inhibitor Gossypol stops proliferation of MSP RAS cells.  
(A) HMLE RAS cells were seeded in duplicates in 12-well plates. 4h after seeding direct cell counting was per-
formed by defining the cell number/well with a Celigo® cytometer for the indicated time periods. (B, C) 24h af-
ter seeding HMLE RAS cells were treated with 6-30µM Gossypol for 24h. Afterwards, the cells were washed 
with supplemented MEGM medium and kept in culture. Cell number was measured once a day for 8 days with a 
Celigo® cytometer after adding fresh medium. DMSO-treated cells were used as control. Data show mean ±SD. 
One representative experiment of n=2 is shown.  
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Figure 5.18: The Bcl-xL inhibitor Gossypol induces autophagy in MSP RAS cells.  
16h after seeding HMLE RAS cells were exposed to 5µM or 10µM Gossypol in the presence or absence of Cis-
platin for 16h. Afterwards, cells were harvested and lysates were analyzed for apoptosis by western blotting. Ac-
tin staining was used as loading control, while LC3a/b staining was used as indicator for autophagy. Accumula-
tion of LC3a/b II indicates autophagy. Non-treated and DMSO-treated cells were used as control. Arrows are in-
dicating the intended staining. For Bcl-xL: * indicates deamidated protein, # indicates unmodified protein. 
n=1. 
5.3.2 HSP90 inhibition destabilizes Bcl-xL and induces apoptosis in MSP RAS cells 
As Caldas-Lopes et al. have shown that Bcl-xL is a client of HSP90 and is therefore protected 
from proteasomal degradation [137], we were interested to see, whether HSP90 inhibition can 
destabilize Bcl-xL and may this affect the response to Cisplatin treatment. For this, we made 
use of the HSP90 inhibitors 17AAG as well as 17DMAG which disable the ATP binding site 
of HSP90 and thereby abolish HSP90 function [138]. MSP RAS cells were treated with 
HSP90 inhibitors for 24h followed by exposure to Cisplatin for 16h. Subsequently, the protein 
lysates were analyzed for Bcl-xL and induced apoptosis by western blot. We found that the 
inhibition of HSP90 in the absence of Cisplatin induced a decrease of Bcl-xL protein level as-
sociated with active Caspase3 and cleaved PARP. The induction of apoptosis was enhanced in 
the presence of Cisplatin. The decrease of Akt protein level indicated the efficiency of the 
HSP90 inhibitors and is well detectable in the presence or absence of Cisplatin (Figure 
5.19A). Next, it was tested whether the overexpression of Bcl-xL in 24
+
HMLE cells and MSP 
cells rescued the induction of apoptosis mediated by HSP90 inhibition. Indeed, neither in the 
absence nor in presence of Cisplatin apoptosis was induced in HMLE overexpressing Bcl-xL 
(Figure 5.19B).  
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It can be concluded that the inhibition of HSP90 results in a decrease of Bcl-xL level which in 
turn sensitizes MSP RAS cells to Cisplatin treatment. The high Bcl-xL levels in expression 
vector-containing HMLE cells rescued these cells from the induction of apoptosis mediated 
by HSP90 inhibition. This implicates that Bcl-xL plays a role in this apoptosis induction.  
 
 
Figure 5.19: HSP90 inhibition sensitizes MSP RAS cells towards Cisplatin.  
(A) 16h after seeding MSP RAS cells were treated with 5µM 17AAG or 17DMAG for 24h. Subsequently, cells 
were washed and exposed to 20µM Cisplatin for 16h. Thereafter, cells were harvested and lysates were analyzed 
for apoptosis and Bcl-xL by western blot. * indicates deamidated protein, # indicates unmodified protein. 
n=3. (B) 16h after seeding 24+Bcl-xL, MSP Bcl-xL and MSP RAS were treated with 5µM 17AAG for 24h. Af-
terwards, the cells were washed and treated with 40µM Cisplatin for 16h. Then, cells were harvested and ana-
lyzed for apoptosis and Bcl-xL by western blot. n=1. Actin staining was used as loading control, while Akt stain-
ing was used as positive control for the experiment. DMSO-treated cells were used as control. Arrows are indi-
cating the intended staining. 
Interestingly, the HSP90 inhibition with 17AAG and 17DMAG resulted in decreased Bcl-xL 
mRNA level, as well (Figure 5.20A). To examine, whether HSP90 directly causes a decrease 
in Bcl-xL mRNA level we performed a siRNA-mediated knock down of HSP90 and analyzed 
the Bcl-xL mRNA level 48h post-transfection with qRT-PCR. It was detectable that HSP90 
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knock down results in decreased Bcl-xL mRNA level, as well. However, this decrease was 
less prominent than that induced by 17AAG-mediated HSP90 inhibition (Figure 5.20B). 
These data implicate that not only HSP90-mediated direct Bcl-xL protein stabilization is im-
portant for the Bcl-xL level in MSP RAS cells. Rather, the stabilization of other HSP90 cli-
ents affects Bcl-xL gene expression in these cells as well. 
 
 
Figure 5.20: HSP90 inhibition decreases Bcl-xL mRNA level.  
(A) 16h after seeding MSP RAS cells were treated with 5µM 17AAG or 17DMAG for 24h. Subsequently, cells 
were harvested and mRNA was isolated. mRNA levels of Bcl-xL were analyzed using qRT-PCR. DMSO-treated 
cells were used as control. (B) 48h after siRNA-mediated knock down of HSP90α and HSP90β, cells were har-
vested, mRNA was isolated and mRNA levels of HSP90pan and Bcl-xL were analyzed by qRT-PCR. Non-
transfected cells and scr siRNA were used as control. mRNA levels were normalized to 36B4. siRNA data show 
mean ±SD of n=3. Student´s t-test was performed for statistical analyses. 
5.3.3 HSP90 inhibition reduces MSP RAS cell-derived tumors in mice 
Previous results suggest the possibility to overcome the chemoresistance of MSP RAS cells 
by inhibiting HSP90 with 17DMAG. To this end, we were interested to examine whether 
MSP RAS cell-derived tumors in mice respond to 17DMAG under physiological conditions 
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as it was the case for MSP RAS cells in vitro. To test this, MSP RAS cells were injected into 
three week old (Nu/Nu) mice. In the phase of exponential tumor growth three weeks after in-
jection, xenograft mice were treated with intraperitoneal injection of 17DMAG 5d per week 
until sacrifice. Tumor size was defined every day and plotted against time. This first 
experiment demonstrated that, 17DMAG treatment resulted in reduced tumor sizes compared 
to the control mice. This effect was reduced during the rest of the treatment (Figure 5.21).  
These results support the notion that HSP90 inhibition constitutes a possibility to overcome 
chemoresistance in MSP RAS cells. Moreover, these findings suggest that this is even possi-
ble under physiological conditions in mice. However, these first data have to be verified with 
a larger number of mice. 
 
 
Figure 5.21: HSP90 inhibition via systemic 17DMAG treatment induces growth inhibition of MSP RAS 
cell-induced tumors in mice. 
10
6
 MSP RAS cells were subcutaneously injected in (Nu/Nu) mice. Three weeks after injection, xenograft mice 
were treated with intraperitoneal injections of 10mg/kg/day 17DMAG (green line) or vehicle (5% glucose, or-
ange line) 5d per week until sacrifice. During treatment, tumor sizes were monitored every day. (Preliminary da-
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6. Discussion 
The developmental program of Epithelial Mesenchymal Transition (EMT) appears to enable 
cancer cells to disseminate from the primary tumor and form metastasis in distant tissues of 
the organism. In addition, EMT has become a prominent process in the acquisition of chemo-
resistance and cancer regrowth in patients associated with a poor prognosis. In order to inves-
tigate about how EMT results in chemotherapeutic resistance we were provided with the 
HMLE and HMLE RAS model systems for EMT by Weinberg and colleagues (MIT Boston, 
USA), consisting of the 24
+
HMLE and MSP cell lines and the 24
+
 RAS and MSP RAS cell 
lines, respectively. 
Our results demonstrated that MSP and MSP RAS cells are resistant to chemotherapeutic 
treatment, including Cisplatin, Carboplatin, Doxorubicin and Neocarzinostatin. Most striking-
ly, we found that MSP and MSP RAS cells acquire the ability to prevent the induction of 
apoptosis, through intrinsic or extrinsic apoptosis signalling pathway. In particular, we identi-
fied the anti-apoptotic Bcl-2-family member Bcl-xL to be overexpressed in MSP as well as 
MSP RAS cells, which causes apoptosis-resistance. Inhibition of Bcl-xL with the BH3 mimic 
Gossypol resulted in chemosensitivity in MSP RAS cells. The same observation was obtained 
upon destabilization of Bcl-xL, mediated by inhibition of HSP90 chaperone function in MSP 
RAS cells in vitro and in vivo. Thus, our results point out a potential strategy to overcome 
chemoresistance in cells that have undergone EMT.  
In conclusion, Bcl-xL appears to be a key factor of apoptosis in cells upon EMT. We propose 
a causal relation between EMT, chemoresistance and Bcl-xL overexpression, and we suggest 

















Figure 6.1: EMT renders HMLE and HMLE RAS cells resistant to chemotherapy by the overexpression 
of Bcl-xL. 
EMT results in the up-regulation of the anti-apoptotic protein Bcl-xL, which in turn prevents cell death in cells 
that have undergone EMT. The inhibition of the chaperone HSP90 affects Bcl-xL stabilization, which results in 
decreased Bcl-xL level and induced apoptosis. However, further HSP90 clients are involved in Bcl-xL transcrip-
tional regulation, which can result in decreased Bcl-xL protein level and induced apoptosis upon HSP90 inhibi-
tion as well. The BH3 mimic Gossypol associates with the BH3-domain of Bcl-2-family members and neutraliz-
es their function. Thus, Gossypol treatment lead to cell death in MSP RAS cells. 
6.1 EMT renders HMLE and HMLE RAS cells resistant to chemotherapy 
6.1.1 Other examples of EMT correlating with chemoresistance 
The process of EMT in cancer cells is not only associated with an invasive and migratory 
phenotype. Rather, EMT results in cancer cells that gain the ability to escape conventional 
chemotherapy by acquiring chemoresistance [85]. Based on this knowledge we asked whether 
EMT affects the response to chemotherapeutics in the HMLE and HMLE RAS system and 
treated them with Cisplatin, Carboplatin, Doxorubicin and Neocarzinostatin. Indeed, we 




 RAS cells, but not in MSP or MSP 
RAS cells, displayed by cleaved Caspase 3 and cleaved PARP (Figure 5.2A-C, Figure 5.6A-
C). Consistent with our findings, Tryndyak et al. defined a correlation between EMT in the 
human breast cancer cell lines MDA-MB-231 and BT-549, and chemoresistance to Doxorubi-
cin [139]. Correspondingly, Asiedu et al. have shown that induced EMT in the epithelial 
mouse mammary carcinoma cell line MMC resulted in mesenchymal cells (ETTM) that were 
resistant to Oxaliplatin, Taxol and Etoposide [140]. Additionally, Arumugam et al. observed 
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that EMT mainly triggered by the overexpression of the transcription factor Zeb1 in these cell 
lines renders human pancreatic cancer cell lines multidrug resistant to Cisplatin, Gemcitabine 
and 5´-FU [141]. Similar findings were observed for Zeb2-overexpressing bladder cancer 
cells, which are resistant to UV- and Cisplatin-induced apoptosis, distinguished by the lack of 
activation of Caspase 3 and cleaved PARP [142]. These results indicated that the induction of 
EMT leads to chemoresistance in several cell lines as well as in our EMT model systems, and 
results in the failure to induce apoptosis upon treatment.  
6.1.2 Impact of cell proliferation and drug uptake 
To stress a possible mechanism for the chemotherapeutic resistance, we initially investigated 
the cell proliferation of cells before and upon EMT. It was recently published that EMT acti-
vators are concomitant with impaired proliferation activity, which is assumed to protect cells 
from DNA damage and would result in delayed apoptosis induction after chemotherapeutic 
treatment [122; 123]. We therefore wanted to define whether different growth rates correlate 
with to the failure of apoptosis induction in MSP and MSP RAS cells. In fact, our results 
show that MSP cells displayed decreased growth rates compared to the 24
+
 HMLE cells after 
Cisplatin treatment. However, the growth rates of 24
+
 RAS and MSP RAS cells were compa-
rable (Figure 5.3A, B mock). We assumed that the latter observation is caused by the overex-
pression of the RAS-oncogene, which is known to increase cell proliferation by induction of 
Cyclin D1 and might therefore be mediating similar growth behavior in the HMLE RAS cell 
system [143]. Since we observed no induction of apoptosis after Cisplatin treatment in both 
cell lines, MSP and MSP RAS, upon EMT, we concluded that different proliferation rates are 
not the reason for this finding. Strikingly, when we treated the cells with Cisplatin for 24h fol-
lowed by prolonged incubation, we observed that MSP RAS cells continued their prolifera-
tion after 5d, while 24
+
 RAS cells did not recover (Figure 5.3B). Considering these findings, 
we asked whether MSP RAS cells gain the possibility to escape Cisplatin treatment by in-
creased drug efflux. We therefore determined the amount of adducts formed by Cisplatin and 
DNA in HMLE RAS cells. However, we did not detect differences between 24
+
 RAS and 
MSP RAS cells (Figure 5.4). Surprisingly, it is especially known for Cisplatin that the ectopic 
expression of the Cu-transporter ATP7A and 7B is associated with decreased Cisplatin sensi-
tivity because of increased Cisplatin export [37]. Beyond that, the surface marker CD44 con-
tributes to drug resistance via the interaction with the ABC-transporter P-glycoprotein, which 
is involved in drug efflux, as well [34; 144]. The expression of CD44 is assumed to induce a 
metastatic phenotype in locally growing tumor cells and is highly induced in MSP and MSP 
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RAS cells [110; 145]. However, our finding that both cell lines contained comparable 
amounts of Cisplatin adducts after treatment suggests that Cisplatin transport processes are 
not involved in apoptosis resistance of MSP RAS cells.  
In summary, we have shown that EMT results in MSP and MSP RAS cells which are resistant 
to distinct chemotherapeutics. Further, we demonstrated that neither differences in the cell 
proliferation nor drug efflux protect MSP RAS cells from chemotherapy.  
6.1.3 Manipulation of EMT-associated pathways fails to sensitize MSP RAS cells 
EMT is executed by the activation and modification of distinct signalling pathways that might 
result in chemoresistance. On the one hand, an active Wnt-pathway is associated with EMT, 
marked by phosphorylated JNK and, subsequently, overexpression of Jun and active p38 
[110; 126]. On the other hand, TGFβ plays a crucial role in the process of EMT [85]. To as-
sess the relevance of these pathways in cell death resistance in our HMLE RAS system, we 
made use of respective inhibitors in the presence of Cisplatin. We found that the inhibition of 
JNK and p38 as downstream effectors of the Wnt-pathway exhibit no effect on the response 
of MSP RAS cells to Cisplatin. The same observation was obtained upon inhibition of 
Mek1/2 and the TGFβ pathway (Figure 5.5B-D). In contrast to our results, Vangipuram et al. 
suggested a correlation between the active Wnt-pathway and chemoresistance in neuroblas-
toma cell lines, as they successfully sensitized these cells to Doxorubicin by the application of 
specific Wnt-inhibitors [146]. Similar results have been found for chemoresistant human co-
lon cancer cells by Chikazawa et al., whereby the siRNA-mediated knock down of β-Catenin 
diminished Wnt-signalling and retrieved sensitivity of these cells to Paclitaxel [147]. Further, 
it has been demonstrated with cell culture experiments that TGFβ treatment resulted in induc-
tion of reversible EMTs. Thereby, TGFβ withdrawal immediately results in the reversion 
from a mesenchymal to an epithelial phenotype [148]. In contrast to our findings, the block-
age of Mek1/2 resulted in inactivation of the Erk1/2 kinases and inhibition of TGFβ-induced 
EMT in NMUMG cells [149]. Interestingly, Scheel et al. have previously shown that TGFβ 
and Wnt-molecules, such as Wnt5a, are essential for the EMT induction in 24
+
 HMLE, indi-
cating that the Wnt- and TGFβ signalling pathways are indispensible for the EMT in the pre-
sent model system [110]. However, our findings suggest that inhibition of TGFβ and Wnt-
pathways are not sufficient to induce chemosensitivity in MSP RAS cells. Given the fact that 
the MSP as well as MSP RAS cells in our model system reside stably in their mesenchymal 
state [110], we assume that we are working with an EMT system that is associated with large-
ly irreversible epigenetic changes. Thus, we conclude that manipulation of EMT-inducing 
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molecules, such as Wnt or TGFβ, for short time periods is insufficient to revert EMT-induced 
cellular changes that cause chemoresistance.  
6.1.4 MSP RAS cells are resistant to extrinsic apoptosis induction 
We have shown that EMT leads to chemoresistant MSP and MSP RAS cells. However, the 
most striking observation was that MSP RAS cells failed to undergo apoptosis independent of 
the chemotherapeutic treatment we applied. Additionally, we demonstrated that the exposure 
of HMLE RAS cells to death ligands, such as Trail and TNFα, results in the induction of 
apoptosis in 24
+
 RAS cells, but not in MSP RAS cells, indicating that Caspase 8 and Caspase 
3 can only be activated downstream of the mitochondria in these cells (Figure 5.7A, B). Con-
sistent with our findings, it has been recently published that acquisition of multidrug-
resistance upon EMT correlates with altered death receptor signalling [150]. Antoon et al. 
have shown that resistance of the MCF7 breast cancer cell line to TNFα is related to EMT and 
an altered death receptor pathway, blocking extrinsic apoptosis. They hypothesized that al-
tered TNF receptor expression switched TNF ligand binding from cell death to pro-survival 
signals in these cells. These changes made MCF7 cells resistant to the clinical chemothera-
peutic agents Trail, Etoposide, Paclitaxel and Doxorubicin and was accompanied by increased 
tumorigenesis [150]. Interestingly, a very recent report demonstrated that the gene expression 
of FAS and TNF signalling mediators was down-regulated by the anti-apoptotic protein Bcl-
xL, which is a common protein involved in chemoresistance [151; 152]. In this context, the 
next step is to investigate whether the protein level of death receptors, mediating extrinsic 
apoptosis, are differentially present in MSP RAS compared to 24
+
 RAS cells. Further, it is 
known that increased expression of anti-apoptotic Bcl-2 family members, such as Bcl-2 and 
Bcl-xL, and decreased expression pro-apoptotic Bcl-2 family members, like Bax and Bid, rep-
resent prominent resistance mechanisms that disrupt mitochondria-initiated apoptosis in 
breast cancer [150; 152]. However, as of yet, these findings have not been directly linked to 
EMT. Taken together, the failure to induce apoptosis in cells that have undergone EMT raises 
the idea that EMT results in changes to the downstream cellular machinery involved in apop-
tosis.  
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6.2 The anti-apoptotic protein Bcl-xL as a mediator of chemoresistance in cancer cells  
6.2.1 Bcl-xL protects MSP RAS cells from apoptosis 
Within our studies we observed that the anti-apoptotic Bcl-2-family member Bcl-xL is over-





 RAS cells, respectively (Figure 5.8A-C). Correspondingly, we have 
demonstrated that the overexpression of Bcl-xL in 24
+
 HMLE renders these cells resistant to 
chemotherapy, as well as to the initiation of extrinsic apoptosis via treatment with Trail 
(Figure 5.10). Conversely, siRNA-mediated knock down of Bcl-xL in MSP RAS cells ren-
dered them sensitive to death stimuli (Figure 5.9A-C). Consistent with our observations, 
Kunze et al. have shown that not only the siRNA-mediated knock down of Bcl-2, Bcl-xL, but 
also the reduction of XIAP (X-linked inhibitor of apoptosis) or survivin, sensitize chemo-
resistant bladder cancer cells to chemotherapy, including mitomycin C and Cisplatin treat-
ment [153]. Knockout studies revealed important roles for the Bcl-2 family members Bcl-2, 
Bcl-xL and Mcl1 in oncogenesis [35]. However, upon EMT we were not able to detect differ-
ences in the expression of anti-apoptotic proteins, except Bcl-xL (Figure 5.8D). The first di-
rect evidence that elevated Bcl-xL levels play an important role in cancer was demonstrated 
by Packham et al. in 1998 in murine leukemia cells [154]. In the meantime, overexpression of 
Bcl-xL was found in several cancers, such as hepatocellular carcinoma, prostate cancer, colo-
rectal cancer and also breast cancer [76; 79]. Fernández et al. induced plasmid-mediated Bcl-
xL overexpression in human breast cancer cell line MDA-MB-435, which resulted in an in-
crease in the metastatic potential of these cells, an attribute that is also found in MSP RAS 
cells [80; 110]. Correspondingly, Martin et al. have shown that Bcl-xL expression did not in-
duce tumor formation, but enhanced metastatic potential in breast tumor cell lines [155]. Con-
sistent with these findings, Bcl-xL overexpression counteracts the pro-apoptotic signals re-
leased in the microenvironment of primary and disseminated tumors and promotes successful 
development of metastasis in the organism [156]. These data support our findings of Bcl-xL-
mediated chemoresistance in MSP RAS cells.  
We further have demonstrated that Bcl-xL protein levels were heterogeneous within the in-
vestigated breast cancer samples, as well. The presence of different Bcl-xL protein levels did 
not correlate with breast cancer subtypes or the parameters Her2-status, hormone receptors, 
stage, sex and age (Figure 5.11A, B) [personal communication A. Scheel]. Interestingly, six 
investigated cases displayed pronounced Bcl-xL protein level in tumor cells at the tumor-
stroma-interface and in disseminated tumor cells, supporting previously published results that 
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Bcl-xL is associated with metastatic potential (Figure 5.11A-C). Consistent with our findings, 
Olopade et al. examined 42 human invasive breast cancer samples for their expression of Bcl-
xL by immunohistochemical and immunoblot methods [157]. Their studies revealed that 43% 
of these samples contain increased levels of Bcl-xL. The overexpression of Bcl-xL in these 
tumors was associated with higher tumor grade and decreased overall survival. Additionally, 
they found no correlation between age, tumor size, ER-status or p53-status, which correlates 
well with our results.  
We furthermore determined that the disseminated cells in our breast cancer samples and the 
occurrence of the mesenchymal marker N-Cadherin partly overlapped with Bcl-xL expression 
[A. Scheel, personal communication], which probably indicates phenotypic changes resem-
bling an EMT-like process. Hitherto, the correlation between EMT and the overexpression of 
anti-apoptotic proteins has been shown for Bcl-2, but not for Bcl-xL. There is significant evi-
dence for the association of the prevalence of CD44 in breast cancer samples with increased 
Bcl-2 expression, indicating that the CD44
+
-population of breast cancer cells is potentially 
more resistant to apoptosis [158]. Additionally, given the fact that primary human mammary 
epithelial cells (HMECs, without large T-antigen) did not display an up-regulation of anti-
apoptotic proteins in comparison to human embryonic stem cells (hESCs) and human cancer 
cells, we suggest that the up-regulation of Bcl-xL in MSP and MSP RAS cells, originating 
from HMLE, is correlated with the process of EMT [159].  
In conclusion, our data demonstrate Bcl-xL as a key factor of inhibition of apoptosis in our 
EMT systems. Further, the expression of Bcl-xL appears to be increased in a significant frac-
tion of invasive breast cancers [157], however the general role for Bcl-xL in EMT in breast 
cancer requires the investigation of a larger collective to be strongly proven. 
6.2.2 Bcl-xL level in MSP RAS cells are not detectably regulated by miRNAs or candi-
date transcription factors 
miRNAs play an important role in the process of EMT, particularly the families let-7 and 
miR-200. While the loss of let-7 in cancer results in reverse embryogenesis and dedifferentia-
tion, miR-200 has been shown to be a prominent regulator of EMT [130]. Based on these 
findings, we examined the presence of miRNA let-7a, let-7b and let-7f in MSP RAS cells. 
However, our results demonstrated that the levels of those miRNAs did not differ in 24
+
 RAS 
compared to MSP RAS cells (Figure 5.13A). In contrast to our results, Li et al. have shown 
that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d and let-7e were significantly 
down-regulated in chemoresistant pancreatic cancer cells, which showed EMT characteristics 
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[160]. Further, they observed that the up-regulation of miR-200 results in the reversion of 
EMT and increased chemo-sensitivity in Gemcitabine-resistant MiaPaCa-2 pancreatic cancer 
cells. Beyond that, Shimizu et al. characterized the let-7 family as inhibitors for Bcl-xL gene 
expression [79]. They have shown that Bcl-xL is overexpressed in human hepatocellular car-
cinoma associated with increased survival. The authors defined with reporter assays a direct 
post-transcriptional regulation, involving miRNA let-7 and the 3´UTR of Bcl-xL mRNA. 
Shimizu et al. have further demonstrated that low expression of let-7 miRNA was accompa-
nied by high Bcl-xL level, while induced let-7 expression resulted in down-regulation of Bcl-
xL and induced apoptosis after chemotherapy [79]. In contrast to our data, these results indi-
cate a role for miR let-7 in the regulation of Bcl-xL gene expression. 
To exclude that Bcl-xL levels are regulated by other miRNAs than specifically determined in 
TaqMan gene expression assays, we performed a siRNA-mediated knock down for Dicer, a 
component which is necessary for the maturation of pre-miRNA to miRNA. In the case of 
miRNA-mediated regulation of Bcl-xL, we expected an increase in the level of Bcl-xL in 24
+
 
RAS cells after Dicer knock down. However, Dicer knock down affected neither the level of 
Bcl-xL in 24
+
 RAS nor in MSP RAS cells (Figure 5.13B, C). Given these facts, we have not 
confirmed previous findings that Bcl-xL is regulated by miRNAs. Even though we did not 
examine all members of the miR let-7 family, we conclude from the Dicer knock down exper-
iment that neither miRNA let-7 nor other miRNAs play a significant role for the Bcl-xL ex-
pression in our cell system.  
 
Further, it has been shown that the Bcl-xL promoter region contains several transcription fac-
tor binding sites, including sequences for the binding of the transcription factors AP-1, STAT, 
Ets and NFκB, implicating various regulatory mechanisms [72; 76]. We therefore subsequent-
ly determined the effects of the transcription factors AP-1 and STAT3/5 on Bcl-xL level in 
MSP RAS cells. We have shown that siRNA-mediated knock down of AP-1 via the reduction 
of cJun, cFos and JunD did not affect Bcl-xL protein level (Figure 5.14B, Figure 5.15A-D). 
The same observation was obtained for siRNA-mediated knock downs of STAT3 and 
STAT5, which did not result in altered Bcl-xL mRNA or protein levels either (Figure 5.16A-
C). In contrast to our findings, Salameh et al. demonstrated the presence of two functional 
AP-1 binding sites in the Bcl-xL promoter which can be recognized by the heterodimer 
cJun:ATF2 [161]. Silencing of cJun or ATF2 resulted in decreased Bcl-xL level [161]. Fur-
ther, STAT3 and STAT5 are especially known to be involved in the regulation of Bcl-xL gene 
expression [72; 76]. However, our data suggest that diminished levels of the transcription fac-
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tors AP-1 and STAT3/5 have no impact on Bcl-xL protein level. On the one hand, it is possi-
ble that these transcription factors are quite stable, because of their association to the chroma-
tin. This would require the performance of extended knock down or stable knock down exper-
iments, mediated by shRNA instead of siRNA. On the other hand, combinations of siRNAs 
can evoke reduced knock down efficiencies and effects on the target proteins. Thus, we are 
going to verify these results with single instead of combined siRNA knock downs to make our 
final conclusions from this experiment.  
 
Another transcription factor which is associated with Bcl-xL gene expression is NFκB. NFκB 
has been found to promote tumorigenesis, which is mediated by the protection of cancer cells 
from the induction of apoptosis [162]. Correspondingly, Wang et al. suggested that NFκB 
promotes resistance in breast cancer cells by induced gene expression of Bcl-xL and IAPs 
(inhibitor of apoptosis) [163]. Moreover, Huber et al. have shown that the IKK-2/IκBα/NFκB 
pathway is required for the induction and maintenance of EMT in breast cancer. Thus, the in-
hibition of this pathway prevents EMT and in contrast, activation leads to a mesenchymal 
phenotype [164]. We hypothesize that EMT possibly results in activation of the NFκB signal-
ling pathway, which subsequently induces the overexpression of Bcl-xL in the MSP RAS 
cells. In this context, it would be interesting to characterize the role of NFκB in correlation to 
EMT and Bcl-xL gene expression in our model system. Consequently, the investigation of 
NFκB activity as well as the inhibition of the respective factors could be helpful to elucidate 
the regulation of Bcl-xL expression. 
 
Additionally, concerning Bcl-xL regulation, recent reports defined the 5´UTR of Bcl-xL as a 
key regulatory element, which controls the translation of Bcl-xL mRNA [165]. Yoon et al. 
demonstrated that the 5´UTR of Bcl-xL mRNA contains an IRES (internal ribosome entry 
side) sequence, which is used in cells under stress [166]. Additionally, Durie et al. have 
shown that the RNA binding protein HuR (Hu antigen R) specifically binds to the 5´UTR of 
Bcl-xL, which results in the repression of Bcl-xL translation [165]. A separate assay would be 
required to examine translation in MSP RAS and 24
+
 RAS cells. To this end, a polyribosome-
analyses assay would be useful to make a declaration about the efficiency of the mRNA trans-
lation in both cell lines.  
 
Taken together, we manipulated several cellular molecules to investigate the effects on Bcl-
xL levels and on chemoresistance in MSP and MSP RAS cells. However, we were not able to 
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confirm previous findings concerning Bcl-xL regulation by miRNAs and specific transcrip-
tion factors in our HMLE RAS system. We do not exclude the regulation of Bcl-xL or EMT 
by the addressed molecules, albeit we assume that missing effects could be due to the fact that 
we targeted modulatory mechanisms separately. The complexity of the EMT process suggests 
that reduction of Bcl-xL levels in MSP and MSP RAS cells probably needs a wide range of 
manipulating events, which in the end result in chemosensitive cells. Nevertheless, we suc-
cessfully aimed to overcome the chemotherapeutic resistance in MSP RAS cells, using rea-
gents that are already established in clinical trials. 
6.3 Targeting Bcl-xL in MSP RAS cells to overcome chemoresistance 
6.3.1 Gossypol induces autophagy in HMLE RAS cells  
The overexpression of the anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL have been 
found to contribute to metastasis and to interfere with the anti-tumor activity of chemothera-
peutic drugs in cancer cells [155; 167]. It is possible that cancer cells develop a dependence 
on the protective effect of Bcl-2 and Bcl-xL for their survival [168]. Therefore, several studies 
pursued the development of anti-tumor agents that restore the apoptotic process. These anti-
tumor agents sensitize resistant cancer cells to chemotherapy, by targeting the anti-apoptotic 
functions of Bcl-2 and Bcl-xL [167]. An inhibitor that specifically interacts with anti-
apoptotic Bcl-2 family members like Bcl-2 and Bcl-xL is Gossypol. This agent is a polyphe-
nol, isolated from cotton seeds. Gossypol binds to the BH3-domain of anti-apoptotic proteins 
to neutralize their function [169]. Our aim was to examine whether Gossypol treatment sensi-
tizes MSP RAS cells to chemotherapy. We have demonstrated that the application of Gossy-
pol to HMLE RAS cells resulted in a proliferation stop in 24
+
 RAS, as well as in MSP RAS 
cells (Figure 5.17A-C). In fact, we did not observe that Gossypol induces apoptosis in these 
cells, but rather autophagy (Figure 5.18). This observation was previously described by Gao 
et al., providing evidence that Gossypol induces autophagy followed by apoptotic cell death 
in MCF7 cells [135]. Mechanistically, they have shown that the BH3-only protein Beclin1, 
which is an inducer of autophagy, binds to the anti-apoptotic Bcl-2 family members. This in-
teraction inhibits Beclin1 function. However, the dissociation of Beclin1 from its inhibitors 
triggers autophagy in the cell [135]. Gossypol is a BH3 mimetic and therefore able to bind the 
BH3-binding groove of Bcl-2 and Bcl-xL. The interaction between Gossypol and Bcl-2 or 
Bcl-xL interrupts the binding of Bcl-2 or Bcl-xL to the pro-apoptotic Bcl-2 family members 
Bax and Bim, which initiates apoptosis. But it also interrupts the binding of Bcl-2 or Bcl-xL 
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to Beclin1, inducing autophagy. We wonder why we did not detect induced apoptosis, but ra-
ther autophagy in both 24
+
 RAS and MSP RAS cells. Gao et al. hypothesized that, during the 
early stages of Gossypol treatment, the integrity of the mitochondria membranes is relatively 
stable. This results in autophagy as a protective mechanism in the cell, ensuring the turnover 
of damaged mitochondria. However, at later stages or at higher Gossypol dosages, mitochon-
dria outer membrane permeabilization occurs and induces apoptosis. They suggested that au-
tophagy delays the initiation of apoptosis, especially confirmed by the fact that the inhibition 
of autophagy immediately amplified the initiation of apoptosis by Gossypol [135]. In fact, we 
treated HMLE RAS cells for 16h with 5µM and 10µM Gossypol and were unable to detect 
apoptosis induction. Even higher Gossypol concentrations, applied for the long-term prolif-
eration assay, did not reveal typical apoptotic cell shapes of treated cells (Figure 5.17). For 
this reason, we doubt that this explanation applies to our cell system. Interestingly, Lian et al. 
suggested that Gossypol preferentially induces autophagy in apoptosis-resistant cells with 
high Bcl-2/Bcl-xL levels and apoptosis in cells with low Bcl-2/Bcl-xL levels [136]. This im-
plies that the induced mode of cell death by Gossypol is dependent on the cellular context. 
Possibly, in cells containing low Bcl-2/Bcl-xL levels, the inhibition of the interaction with 
pro-apoptotic members of the Bcl-2 family is sufficient to shift the balance towards apoptosis. 
However, in cells with high levels of Bcl-2/Bcl-xL, the initiation of autophagy occurs more 
rapidly due to the inhibition of the interaction of Bcl-2/Bcl-xL with Beclin1 after Gossypol 
treatment [136]. The observation that Gossypol induces autophagy in MSP RAS and in 24
+
 
RAS cells can be explained by the possibility that the Bcl-xL and Bcl-2 protein levels in 24
+
 
RAS cells are probably high enough to prevent the induction of apoptosis after Gossypol 
treatment, rather than autophagy. To verify this idea, we propose to knock down Bcl-xL and 
possibly Bcl-2, followed by Gossypol treatment, to examine the induction of apoptosis. Addi-
tionally, it has been shown for another BH3 mimetic, ABT-737, that this reagent induces au-
tophagy, as well [170]. It would be interesting to verify whether ABT-737 induces autophagy, 
but not apoptosis in the HMLE RAS system, too. Importantly, using reagents that target au-
tophagy to kill cancer cells is a promising new strategy for cancer therapy. Even in our sys-
tem, the application of Gossypol treatment was successful in inhibiting cell proliferation in 
chemoresistant MSP RAS cells, representing a potent reagent to overcome chemoresistance in 
these cells. In this context, Wolter et al. performed xenograft experiments with chemo-
resistant, high Bcl-xL-expressing head and neck squamous cell carcinoma (HNSCC). The au-
thors have shown that the treatment of these tumors with Gossypol resulted in decreased mi-
totic rates and an increase in the number of apoptotic cells in comparison to the control mice 
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[169]. To explore whether Gossypol affects MSP RAS cells under physiological conditions, 
we are going to perform xenograft experiments, treating MSP RAS cell-induced tumors with 
Gossypol.  
 
6.3.2 Bcl-xL destabilization mediated by HSP90 inhibition induced apoptosis in MSP 
RAS cells 
Besides targeting Bcl-xL in MSP RAS cells with Gossypol, we demonstrated that the destabi-
lization of Bcl-xL mediated by HSP90 inhibition sensitized these cells to chemotherapy. Par-
ticularly, the inhibition of the HSP90 chaperone-function with the specific HSP90-inhibitors 
17AAG and 17DMAG resulted in the induction of cleaved Caspase 3 and cleaved PARP in 
MSP RAS cells (Figure 5.19A). Caldas-Lopes et al. have previously shown that Bcl-xL is a 
direct client of HSP90 [137]. Correspondingly to our results, they have demonstrated that the 
inhibition of HSP90 with the inhibitor PU-H71 induced apoptosis in triple-negative Breast 
cancer cells, partly by the inactivation and down-regulation of the anti-apoptotic protein Bcl-
xL, as well as the pro-survival protein Akt [137]. We observed reduced Akt protein levels in 
our experiments, as well. Interestingly, Akt inhibition alone did not induce apoptosis in MSP 
RAS cells, implying that Bcl-xL is essential for preventing apoptosis in our system (Figure 
5.5A). This assumption was further confirmed by the fact that we were not able to induce 
apoptosis after 17AAG-mediated HSP90 inhibition in 24
+Bcl-xL
 and MSP 
Bcl-xL
 cells, which 
continuously express high levels of Bcl-xL (Figure 5.19B). In addition, Nimmanapalli et al. 
have demonstrated that 17AAG treatment resulted in destabilization of the growth- and sur-
vival-signalling proteins c-Raf-1, Akt and c-Src; and additionally, in the conformational 
change of the pro-apoptotic protein Bax [171]. However, when they overexpressed Bcl-xL in 
human leukemic cells (HL-60) and human breast cancer cells (MDA-MB-468), they also 
failed to induce apoptosis after 17AAG treatment. In fact, this could not be explained by the 
failed destabilization of further HSP90 client proteins, which were still decreased upon 
HSP90 inhibition, but rather by the lack of mitochondrial events of apoptosis, supporting our 
findings in 24
+Bcl-xL
 and MSP 
Bcl-xL
 cells [171]. These results indicate that Bcl-xL stabilization 
in MSP RAS cells is in part mediated by HSP90, confirmed by the marked decrease in Bcl-xL 
protein levels after HSP90 inhibition, which contributed to apoptosis in MSP RAS cells and 
the failed induction of apoptosis in Bcl-xL overexpressing HMLE cells. 
Further, it has been shown for mammary tumors that they contain increased levels of anti-
apoptotic Bcl-2 family members, as well as increased levels of the heat shock proteins HSP70 
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and HSP90 [172]. It is suggested that HSP70 and HSP90 are able to inhibit the apoptotic cas-
cade by preventing the formation of the apoptosome or induction of Fas signalling, which 
contributes to the formation of malignant cells [173; 174; 175]. In contrast to these findings, 
we did not detect increased HSP90 levels in MSP RAS compared to 24
+
 RAS cells, implying 
that HSP90 is not executing these functions in MSP RAS cells to prevent apoptosis (data not 
shown). However, considering the high number of HSP90 clients which are stabilized by 
HSP90, we assume that not only HSP90-mediated Bcl-xL stabilization plays a role for the in-
duction of apoptosis in MSP RAS cells after HSP90 inhibition. Rather, the destabilization of 
transcription factors, such as STAT3 and STAT5, which are involved in Bcl-xL gene expres-
sion, or EMT-regulating factors, like NFκB, which possibly maintain the mesenchymal state 
of the MSP RAS cells, may be important for the induction of apoptosis after abolishing 
HSP90 chaperone function [176; 177]. Possibly, the inhibition of EMT-inducing molecules 
and Bcl-xL transcription factors, mediated by HSP90 inhibition, is necessary to induce a de-
crease in Bcl-xL levels in MSP RAS cells and subsequently apoptosis. 
 
17AAG and 17DMAG are promising anti-tumor agents, which are already used in clinical tri-
als [178; 179]. We performed one preliminary xenograft experiment, treating MSP RAS cell-
induced tumors with 17DMAG (Figure 5.21). We have demonstrated that in comparison to 
the control group 17DMAG treatment resulted in reduced tumor sizes. 17DMAG displays less 
hepatotoxicity compared to 17AAG and is easily soluble in water [180; 181]. In addition, in 
vitro clonogenic assays revealed lower IC50 for 17DMAG than for 17AAG, implicating that 
17DMAG is a more potent anti-tumor drug [182; 183]. The efficacy of 17DMAG has been 
verified in several xenograft models, including MDA-MB-231 (breast cancer) and NCI-H522 
(adenocarcinoma). Clinical phase I studies have shown that HSP90 inhibition in Her-2 posi-
tive breast cancer cells combined with Trastuzumab, a cytostatic agent used for breast cancer, 
is well tolerated and inhibits tumor growth in vivo [184]. Our first result indicates that we are 
able to overcome the resistant phenotype of MSP RAS cells in vivo by inhibiting HSP90 in 
mice. Considering the characteristics of MSP RAS cells, such as being cells that have under-
gone EMT, containing stem cell like properties, being highly invasive and forming metastasis, 
we are now able to target such cells, resulting in inhibited tumor growth in vivo and chemo-
sensitivity in vitro.  
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6.3.3 The role of Salinomycin in treating cancer stem cells 
Another agent that is able to specifically eliminate cancer stem cells (CSC), an attribute that is 
associated with our MSP RAS cells as well, is Salinomycin. Salinomycin was found by per-
forming a high throughput screen to identify selective inhibitors for CSC [185]. Salinomycin 
is a ionophore antibiotic with the ability to kill CSC as well as chemoresistant tumor cells 
[186]. Indeed, by the performance of long-term-survival assays, we have shown that MSP 
RAS cells are more sensitive to Salinomycin than 24
+
 RAS cells (Figure 8.1, appendix). Hith-
erto, Salinomycin was only used in veterinary medicine. However, Gupta et al. showed in 
previous studies that Salinomycin is 100 times more efficient in killing breast cancer stem cell 
like cells than Taxol [185]. Interestingly, Gupta et al. used human breast cancer cell lines for 
their investigations, which have been experimentally induced to undergo EMT. Particularly, 
they worked with HMLE and HMLE RAS cells and induced EMT on the one hand via 
shRNA-mediated gene silencing of E-Cadherin and on the other hand via the overexpression 
of the EMT-transcription factor Twist. Both experimental settings resulted in cells that have 
undergone EMT associated with a mesenchymal phenotype. Nevertheless, upon EMT cells 
displayed resistance towards the chemotherapeutic drugs Paclitaxel (~20 fold increase in IC50) 
and Doxorubicin (~5 fold increase) compared to the respective HMLE and HMLE RAS con-





 cells by 20-fold in comparison to the controls and additionally, 
decreased the number of tumor-spheres by 10-fold [185]. Despite these impressive findings, 
an important caveat for the clinical use of Salinomycin is its toxicity [186]. It is known that 
Salinomycin exhibits toxicity towards neuronal cells and additionally reduces cell viability 
[187]. An important fact is that Salinomycin can only be applied by intravenous injection, be-
cause the oral application of Saliomycin results in life-endangering rhabdomyolysis [188]. 
This particular disadvantage of Salinomycin should be considered when establishing this an-
tibiotic as an anti-cancer reagent. In contrast, the HSP90 inhibitors 17AAG and 17DMAG, 
which work efficiently in our EMT system to eliminate MSP RAS cells, are well established 
within clinical trials and do not show any detrimental activity.  
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6.4 Relevance of our findings in human cancer diseases and future aspects 
6.4.1 Migrating breast cancer cells combine the attributes of EMT and Bcl-xL overex-
pression 
The presence of EMT in human cancer has been intensely discussed during the last decades. 
Findings in pre-clinical models suggest that at least a partial EMT occurs during cancer pro-
gression, supporting tumor metastasis and chemoresistance [93]. Within our studies, we have 
demonstrated that EMT renders HMLE as well as HMLE RAS cells resistant to chemothera-
py and particularly resistant to apoptosis induction mediated by the overexpression of Bcl-xL. 
Correspondingly, we made use of immunohistochemical approaches to characterize Bcl-xL 
protein levels in human breast cancer tissues (Figure 5.11A-C). We found increased Bcl-xL 
protein levels at the stroma interface and in disseminated tumor cells. Staining for Cytokeratin 
8 indicated that the disseminated tumor cells belong to the tumor, but not to stroma (Figure 
5.11D). In this context, it has been previously shown that the dissemination of tumor cells is a 
prerequisite to form metastasis associated with EMT at the invasive front [93; 94; 189]. Not 
only is the autonomous activation of EMT-relevant pathways required, but rather co-
stimulatory signals from the microenvironment at the tumor-stroma interface are necessary to 
induce EMT [189]. Additionally, the accumulation of genetic alterations occurs in these cells, 
providing them with the ability to survive in distant tissues [189]. In fact, Brabletz et al. sug-
gested the presence of migrating cancer stem (MCS) cells at the invasive front, combining the 
attributes of stemness and mobility mediated by EMT [189]. They assumed that breast cancer 
meets both of these attributes of the MCS-cell concept, which explains tumor metastasis 
[189]. Consistently, very recent findings by Yu et al. characterized EMT in circulating tumors 
cells (CTC) from human breast cancer tissues [190]. They found that mesenchymal cells are 
highly enriched in CTCs and proposed an association of mesenchymal CTCs and disease pro-
gression. In particular, the comparison of CTCs in pre- and post-treatment blood samples re-
vealed that progressive disease is associated with increased numbers of mesenchymal CTCs 
[190]. In addition, they defined active EMT-related signalling pathways, including the TGFβ 
and Wnt-signalling pathways, and the EMT-inducing transcription factor Forkhead box pro-
tein C1 (FOXC1) in these cells. These results indicate the presence of EMT in human breast 
cancer samples [190]. Data from these previous studies correlate well with our findings. Dis-
seminated cancer cells appear to be associated with EMT and the overexpression of Bcl-xL. 
Thus, an important step to define the correlation between EMT and the overexpression of Bcl-
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xL in breast cancer is to prove the presence of EMT-associated transcription factors, such as 
Twist or Zeb1/2, in the disseminated cells from our breast cancer tissue samples.  
6.4.2 Chromosomal rearrangements lead to Bcl-xL overexpression in cancer and em-
bryonic stem cells 
In general, the overexpression of Bcl-xL has not only been detected in breast cancer, but also 
in prostate, colon and pancreatic cancer, as well as multiple myeloma and melanoma [76; 
157]. Our findings suggest that chemoresistance acquired during the process of EMT, even in 
stem cell like cancer cells, is accounted for by the overexpression of the anti-apoptotic protein 
Bcl-xL. Bai et al. found ectopic expression of Bcl-xL in human embryonic stem cells (hESC) 
which resulted in a significant increase of hESC colonies in single-cell suspension cultures 
[151]. This very recent report showed that the overexpression of Bcl-xL in hESCs resulted in 
attenuation of apoptosis, increased efficiency to generate embryoid bodies in vitro and for-
mation of teratoma by dissociated hESCs in vivo. Consistent with these data, findings from 
the initial stem cell initiative revealed that human embryonic stem (ES) cells acquired karyo-
typically changes on prolonged cell culture [191]. In particular, a minimal amplicon in chro-
mosome 20q11.21 occurred in <20% of the investigated ES cell lines. The amplicon includes 
three genes expressed in human ES cells, one of these genes is Bcl2L1 (Bcl-xL is an isoform 
of this gene) [191]. Accordingly, a genome-wide RNAi screen exhibited a prominent role of 
Bcl2L1 in human ES biology [192]. Strikingly, a recent structural variant screen of >3000 
samples from 24 cancer cell types identified a reoccurring gain in 20q11.21, including Bcl2L1 
within the minimal amplicon, as well [191; 193]. In conclusion, these observations imply that 
similar mutations occur in ES and cancer cells, resulting in the overexpression of Bcl-xL. The 
similarity of these mutations suggests equal underlying mechanisms [191]. This raised the 
idea that similar alterations might be present in cells upon EMT, resulting in Bcl-xL overex-
pression. In this context it is of particular interest to analyze the karyotypes of MSP RAS 
compared to 24
+
 RAS cells. These results would give an idea, as to what extent chromosomal 
rearrangements contribute to overexpression of Bcl-xL in MSP RAS cells, leading to chemo-
resistance. 
6.4.3 Gossypol and HSP90 inhibitors as new strategies to eliminate chemoresistant 
cells in human cancer therapies 
Finally, we aimed to find an option to overcome chemoresistance in MSP RAS cells. Anti-
apoptotic proteins are an attractive target for the development of anti-cancer agents, given the 
fact that high levels of anti-apoptotic Bcl-2 family members are associated with chemo-
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resistance [194]. Thus, Fiebig et al. have shown that the overexpression of Bcl-xL in MCF7 
cells is ten times more efficient to render cells chemoresistant than Bcl-2 [81]. We demon-
strated in vitro and in vivo that the BH3 mimetic Gossypol and HSP90 inhibition, respective-
ly, sensitized MSP RAS cells and induced cell death (Figure 5.17C, Figure 5.19A, Figure 
5.21). As mentioned before, both reagents are already established in clinical trials and possi-
bly usable in combinations with conventional therapy to treat cancer. On the one hand, 
17AAG-mediated HSP90 inhibition combined with Trastuzumab was a convincing possibility 
for the treatment of breast cancer patients that are resistant to Trastuzumab alone [195]. Clini-
cal studies revealed mild to moderate toxicities and suggested that HSP90 inhibition in vivo is 
sufficient to cause inhibition of tumor growth [195]. The combination of HSP90 inhibitors 
with chemotherapeutic agents was demonstrated to be additive, as it was shown for 17AAG 
and Carboplatin in ovarian cancer cells. Further, the application of 17AAG in combination 
with Taxol or Doxorubicin in breast cancer cell lines was synergistic, displaying a greater ad-
vantage of 17AAG to treat cancer [196; 197]. On the other hand, Gossypol was tested in sev-
eral clinical trials in which cancer patients were treated with Gossypol in combination with 
conventional therapy. Recent clinical studies investigated the treatment of small cell lung 
cancer and solid tumors with Gossypol in combination with Cisplatin or Etoposide [198]. Fur-
ther, treatments of metastatic cancer and cancers that cannot be removed by surgery were per-
formed using Gossypol in combination with Paclitaxel or Carboplatin [199]. Additionally, 
previous studies in melanoma, colon and breast cancer have demonstrated that Gossypol is 
well tolerated and contributed to reduced tumor volume [200; 201; 202; 203], indicating that 
Gossypol might be applicable for a wide range of cancer types and thus represents a promis-
ing agent for cancer therapy [204]. These results indicate that both reagents, 17DMAG and 
Gossypol, may be considered as anti-cancer drugs for tumor therapies. The fact that both 
chemotherapeutics are able to induce cell death in MSP RAS cells suggests that both reagents 
probably contain the competency to eliminate resistant cells in vivo.  
6.5 Summary 
The data presented here demonstrate that EMT can render cells chemoresistant. We defined 
the anti-apoptotic protein Bcl-xL as a key factor required for chemoresistance, which is over-
expressed in cells that have undergone EMT. si-RNA-mediated knock down of Bcl-xL made 
MSP RAS cells chemosensitive, highlighting Bcl-xL as a promising drug target to sensitize 
cancer cells to chemotherapy. Additionally, our first xenograft experiment revealed HSP90 
inhibitors as possible anti-tumor agents for stemness-associated, metastatic cancer cells. 
6. Discussion  93 
The comparison of our findings to those from previous studies implies a correlation between 
EMT, chemoresistance, cancer stem cell features and Bcl-xL overexpression. Nevertheless, 
further studies are required to define the precise mechanism behind Bcl-xL up-regulation up-
on EMT. However, this report describes Bcl-xL as a key mediator of apoptosis-resistance in 
cells upon EMT and as a determinant of life and death in chemotherapy.  
. 
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List of differentially regulated genes in MSP cells compared to 24
+
 HMLE cells. Micro 
array results. 
The table includes the name of the differentially regulated genes and the NCBI number. In-
duction of gene expression in MSP cells relative to 24
+
HMLE cells is shown as log2, since 
the threshold was set at 2. Positive values indicate up-regulation in MSP cells and negative 
values the down-regulation in MSP cells compared to 24
+
HMLE cells. 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Salinomycin: Survival assay 
 
 
Figure 8.1: MSP RAS cells are sensitive to Salinomycin treatment.  
24h after seeding HMLE RAS cells were treated with 3µM or 6µM Salinomycin. Cell number was measured 
once a day for 3d with a Celigo® cytometer after adding fresh Salinomycin. Non-treated cells were used as con-
trol. Data show mean ±SD. n=1. 
 
 
 
 
